User login
Looking to Orlando for CHEST Annual Meeting 2021
Thinking about best option for attending CHEST 2021 – in-person or online? There are advantages to both.
For attendees who can’t travel because of restrictions, you will have access to all the learning that will take place from Oct 17-20 at CHEST 2021. You can view the sessions through live streaming and access them on demand. CHEST is building an even better delivery platform based on the highly successful online conference last year. Compete in the Players Hub and take part in simulations. We watched last year as participants shared images on social media, showing how they joined the conference. If online is the best option for you, CHEST 2021 will deliver all the learning whenever you can attend.
Joining us in Orlando provides you the opportunity to network with your colleagues, discuss and learn informally, stop by the poster presentations, and visit with exhibitors to hear what’s new to help you in your clinical practice.
Conference center and hotels
CHEST 2021 will be held at the Orange County Convention Center, which has 1.1 million square feet of meeting and exhibition space. This means ample room for social distancing and the ability to adhere to CDC safety protocols. We anticipate there will be changes in guidelines as vaccinations roll out across the country, but CHEST is planning based on procedures currently in place. And we are taking full advantage of all the square footage with wider pathways in the exhibit hall. The Orange County Convention Center is surrounded by hotels, four of them connecting directly to the convention center. Hilton Orlando will serve as the official conference hotel.
Visiting local attractions
You don’t go to Orlando without having a few destinations in mind. If you are planning to visit Disney World, Universal Studio, or SeaWorld, reservations are required. Each park has implemented a reservation system requiring guests and pass members to secure a specific day for their visit in advance. All ticket holders – including single day visitors, multi-day ticket holders, group ticket holders, complimentary ticket holders, seasonal and annual pass members and Fun Card holders – are required to make a reservation at each park before they visit. This is to limit the total number of people in the parks at one time. Same-day reservations may be possible but should not be counted on if visiting the parks is high on your list of things to do.
When it comes to dining and shopping, International Drive – which encompasses the Orange County Convention Center – has a diverse selection of restaurants and entertainment options, ensuring something for everyone. Whether it’s eating at the AAA Four Diamond restaurants at Rosen Shingle Creek or going casual and enjoying the authentically prepared and internationally inspired foods at the Wheelhouse in ICON Park, you’ll find something that satisfies.
Looking for something different? Try an airboat ride across the wetlands of central Florida. See alligators, turtles, birds, and more in their natural environment. Trips include day tours and night adventures. Or take a guided cruise through three of the seven lakes and two narrow canals on the tranquil Winter Park chain.
And, if a few hours in the sunshine chasing a little white ball are to your liking, just down the road from the convention center is a newly redesigned championship golf course by Arnold Palmer Design Company, the Shingle Creek Golf Club. Bring your clubs or rent them at the course.
Grab your friends and colleagues for some fun and try out a few of these places. Maybe even invite the family to join you before or after the conference, and enjoy the getaway.
Thinking about best option for attending CHEST 2021 – in-person or online? There are advantages to both.
For attendees who can’t travel because of restrictions, you will have access to all the learning that will take place from Oct 17-20 at CHEST 2021. You can view the sessions through live streaming and access them on demand. CHEST is building an even better delivery platform based on the highly successful online conference last year. Compete in the Players Hub and take part in simulations. We watched last year as participants shared images on social media, showing how they joined the conference. If online is the best option for you, CHEST 2021 will deliver all the learning whenever you can attend.
Joining us in Orlando provides you the opportunity to network with your colleagues, discuss and learn informally, stop by the poster presentations, and visit with exhibitors to hear what’s new to help you in your clinical practice.
Conference center and hotels
CHEST 2021 will be held at the Orange County Convention Center, which has 1.1 million square feet of meeting and exhibition space. This means ample room for social distancing and the ability to adhere to CDC safety protocols. We anticipate there will be changes in guidelines as vaccinations roll out across the country, but CHEST is planning based on procedures currently in place. And we are taking full advantage of all the square footage with wider pathways in the exhibit hall. The Orange County Convention Center is surrounded by hotels, four of them connecting directly to the convention center. Hilton Orlando will serve as the official conference hotel.
Visiting local attractions
You don’t go to Orlando without having a few destinations in mind. If you are planning to visit Disney World, Universal Studio, or SeaWorld, reservations are required. Each park has implemented a reservation system requiring guests and pass members to secure a specific day for their visit in advance. All ticket holders – including single day visitors, multi-day ticket holders, group ticket holders, complimentary ticket holders, seasonal and annual pass members and Fun Card holders – are required to make a reservation at each park before they visit. This is to limit the total number of people in the parks at one time. Same-day reservations may be possible but should not be counted on if visiting the parks is high on your list of things to do.
When it comes to dining and shopping, International Drive – which encompasses the Orange County Convention Center – has a diverse selection of restaurants and entertainment options, ensuring something for everyone. Whether it’s eating at the AAA Four Diamond restaurants at Rosen Shingle Creek or going casual and enjoying the authentically prepared and internationally inspired foods at the Wheelhouse in ICON Park, you’ll find something that satisfies.
Looking for something different? Try an airboat ride across the wetlands of central Florida. See alligators, turtles, birds, and more in their natural environment. Trips include day tours and night adventures. Or take a guided cruise through three of the seven lakes and two narrow canals on the tranquil Winter Park chain.
And, if a few hours in the sunshine chasing a little white ball are to your liking, just down the road from the convention center is a newly redesigned championship golf course by Arnold Palmer Design Company, the Shingle Creek Golf Club. Bring your clubs or rent them at the course.
Grab your friends and colleagues for some fun and try out a few of these places. Maybe even invite the family to join you before or after the conference, and enjoy the getaway.
Thinking about best option for attending CHEST 2021 – in-person or online? There are advantages to both.
For attendees who can’t travel because of restrictions, you will have access to all the learning that will take place from Oct 17-20 at CHEST 2021. You can view the sessions through live streaming and access them on demand. CHEST is building an even better delivery platform based on the highly successful online conference last year. Compete in the Players Hub and take part in simulations. We watched last year as participants shared images on social media, showing how they joined the conference. If online is the best option for you, CHEST 2021 will deliver all the learning whenever you can attend.
Joining us in Orlando provides you the opportunity to network with your colleagues, discuss and learn informally, stop by the poster presentations, and visit with exhibitors to hear what’s new to help you in your clinical practice.
Conference center and hotels
CHEST 2021 will be held at the Orange County Convention Center, which has 1.1 million square feet of meeting and exhibition space. This means ample room for social distancing and the ability to adhere to CDC safety protocols. We anticipate there will be changes in guidelines as vaccinations roll out across the country, but CHEST is planning based on procedures currently in place. And we are taking full advantage of all the square footage with wider pathways in the exhibit hall. The Orange County Convention Center is surrounded by hotels, four of them connecting directly to the convention center. Hilton Orlando will serve as the official conference hotel.
Visiting local attractions
You don’t go to Orlando without having a few destinations in mind. If you are planning to visit Disney World, Universal Studio, or SeaWorld, reservations are required. Each park has implemented a reservation system requiring guests and pass members to secure a specific day for their visit in advance. All ticket holders – including single day visitors, multi-day ticket holders, group ticket holders, complimentary ticket holders, seasonal and annual pass members and Fun Card holders – are required to make a reservation at each park before they visit. This is to limit the total number of people in the parks at one time. Same-day reservations may be possible but should not be counted on if visiting the parks is high on your list of things to do.
When it comes to dining and shopping, International Drive – which encompasses the Orange County Convention Center – has a diverse selection of restaurants and entertainment options, ensuring something for everyone. Whether it’s eating at the AAA Four Diamond restaurants at Rosen Shingle Creek or going casual and enjoying the authentically prepared and internationally inspired foods at the Wheelhouse in ICON Park, you’ll find something that satisfies.
Looking for something different? Try an airboat ride across the wetlands of central Florida. See alligators, turtles, birds, and more in their natural environment. Trips include day tours and night adventures. Or take a guided cruise through three of the seven lakes and two narrow canals on the tranquil Winter Park chain.
And, if a few hours in the sunshine chasing a little white ball are to your liking, just down the road from the convention center is a newly redesigned championship golf course by Arnold Palmer Design Company, the Shingle Creek Golf Club. Bring your clubs or rent them at the course.
Grab your friends and colleagues for some fun and try out a few of these places. Maybe even invite the family to join you before or after the conference, and enjoy the getaway.
This month in the journal CHEST®
Editor’s picks
Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy and Outcomes. By Dr. Rank, et al.
Long-term Benefits of Pulmonary Rehabilitation in COPD Patients: A 2-Year Follow-up Study. By Dr. A. Yohannes, et al.
Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis. By Dr. E. Cano, et al.
Leadership Essentials for the Chest Physician: Models, Attributes, and Styles. By Dr. J. K. Stoller.
Incidence of Venous Thromboembolism and Bleeding Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. By Dr. D. Jiménez, et al.
Disparities in Sleep Health and Potential Intervention Models: A Focused Review. By Dr. S. Sharma, et al.
Editor’s picks
Editor’s picks
Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy and Outcomes. By Dr. Rank, et al.
Long-term Benefits of Pulmonary Rehabilitation in COPD Patients: A 2-Year Follow-up Study. By Dr. A. Yohannes, et al.
Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis. By Dr. E. Cano, et al.
Leadership Essentials for the Chest Physician: Models, Attributes, and Styles. By Dr. J. K. Stoller.
Incidence of Venous Thromboembolism and Bleeding Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. By Dr. D. Jiménez, et al.
Disparities in Sleep Health and Potential Intervention Models: A Focused Review. By Dr. S. Sharma, et al.
Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy and Outcomes. By Dr. Rank, et al.
Long-term Benefits of Pulmonary Rehabilitation in COPD Patients: A 2-Year Follow-up Study. By Dr. A. Yohannes, et al.
Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis. By Dr. E. Cano, et al.
Leadership Essentials for the Chest Physician: Models, Attributes, and Styles. By Dr. J. K. Stoller.
Incidence of Venous Thromboembolism and Bleeding Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. By Dr. D. Jiménez, et al.
Disparities in Sleep Health and Potential Intervention Models: A Focused Review. By Dr. S. Sharma, et al.
CHEST 2021 moves to Orlando and online – the choice is yours
CHEST is excited to announce that CHEST 2021 will be held in Orlando, Florida, from October 17-21 at the Orange County Convention Center. CHEST 2021 will be offered as both an in-person and online experience. Since travel restrictions remain unknown, CHEST is working to ensure that everyone has access to the same top-tier learning – wherever they are.
“Learning together as a community is an important aspect of the CHEST annual meeting. Whether we are face-to-face or online, the knowledge gained from expert presenters, simulations and games, and talking with one another can’t be duplicated elsewhere. In whatever way you can attend, join us at CHEST 2021 to discuss the critically relevant topics affecting our patients and chest medicine,” said CHEST President Steve Simpson, MD, FCCP.
It is also essential that those who cannot travel can still avail themselves of the engaging and interactive learning offered at the CHEST conference. Everyone – whether online or in-person – will be able to experience the meeting in real-time, including expert faculty presentations, simulated learning experiences, gaming, and more.
What to expect
Through bite-sized, immersive learning, experts in the field will cover the latest updates in pulmonary, critical care, and sleep medicine. CHEST 2021 offers you the opportunity to learn from a diverse set of knowledgeable educators representing different viewpoints and experiences.
Team-based learning is an indispensable component of the annual meeting. The activities support collaborative discovery and help you build relationships with your peers. Known for its development of simulation courses, at CHEST 2021, you can take part in the latest in “hands-on” learning. In addition, gaming will allow for friendly competition among colleagues, whether playing from home or on-site.
Getting involved
Make your mark by submitting your original abstracts and case reports to be presented at CHEST 2021. Because of the past year’s challenges, new discoveries were made in the treatment and approaches to managing chest medicine diseases. This work is important and will inform the way patients receive care in the future.
Showcase COVID-19 research, among other topics you are working on, for a chance to share your findings with colleagues, gain feedback from expert faculty, collaborate with other professionals in the field, and expand your professional portfolio. The deadline to submit is April 28. [link]
Keeping safe
It’s been a long time since in-person conferences were possible. CHEST is closely monitoring the status of the pandemic throughout the planning process. The Orange County Convention Center was selected because the venue is large enough to support social distancing. The CHEST team is establishing protocols that limit the number of individuals in a space, promote good traffic flow, require the wearing of masks, and other safety measures. All on-site participants and CHEST support staff will be required to attest to having received a COVID-19 vaccination to attend.
Continue to watch for more information. Registration for CHEST 2021 will open in May. We’ve missed you, and we look forward to seeing you in Orlando, Florida, October 17-20.
CHEST is excited to announce that CHEST 2021 will be held in Orlando, Florida, from October 17-21 at the Orange County Convention Center. CHEST 2021 will be offered as both an in-person and online experience. Since travel restrictions remain unknown, CHEST is working to ensure that everyone has access to the same top-tier learning – wherever they are.
“Learning together as a community is an important aspect of the CHEST annual meeting. Whether we are face-to-face or online, the knowledge gained from expert presenters, simulations and games, and talking with one another can’t be duplicated elsewhere. In whatever way you can attend, join us at CHEST 2021 to discuss the critically relevant topics affecting our patients and chest medicine,” said CHEST President Steve Simpson, MD, FCCP.
It is also essential that those who cannot travel can still avail themselves of the engaging and interactive learning offered at the CHEST conference. Everyone – whether online or in-person – will be able to experience the meeting in real-time, including expert faculty presentations, simulated learning experiences, gaming, and more.
What to expect
Through bite-sized, immersive learning, experts in the field will cover the latest updates in pulmonary, critical care, and sleep medicine. CHEST 2021 offers you the opportunity to learn from a diverse set of knowledgeable educators representing different viewpoints and experiences.
Team-based learning is an indispensable component of the annual meeting. The activities support collaborative discovery and help you build relationships with your peers. Known for its development of simulation courses, at CHEST 2021, you can take part in the latest in “hands-on” learning. In addition, gaming will allow for friendly competition among colleagues, whether playing from home or on-site.
Getting involved
Make your mark by submitting your original abstracts and case reports to be presented at CHEST 2021. Because of the past year’s challenges, new discoveries were made in the treatment and approaches to managing chest medicine diseases. This work is important and will inform the way patients receive care in the future.
Showcase COVID-19 research, among other topics you are working on, for a chance to share your findings with colleagues, gain feedback from expert faculty, collaborate with other professionals in the field, and expand your professional portfolio. The deadline to submit is April 28. [link]
Keeping safe
It’s been a long time since in-person conferences were possible. CHEST is closely monitoring the status of the pandemic throughout the planning process. The Orange County Convention Center was selected because the venue is large enough to support social distancing. The CHEST team is establishing protocols that limit the number of individuals in a space, promote good traffic flow, require the wearing of masks, and other safety measures. All on-site participants and CHEST support staff will be required to attest to having received a COVID-19 vaccination to attend.
Continue to watch for more information. Registration for CHEST 2021 will open in May. We’ve missed you, and we look forward to seeing you in Orlando, Florida, October 17-20.
CHEST is excited to announce that CHEST 2021 will be held in Orlando, Florida, from October 17-21 at the Orange County Convention Center. CHEST 2021 will be offered as both an in-person and online experience. Since travel restrictions remain unknown, CHEST is working to ensure that everyone has access to the same top-tier learning – wherever they are.
“Learning together as a community is an important aspect of the CHEST annual meeting. Whether we are face-to-face or online, the knowledge gained from expert presenters, simulations and games, and talking with one another can’t be duplicated elsewhere. In whatever way you can attend, join us at CHEST 2021 to discuss the critically relevant topics affecting our patients and chest medicine,” said CHEST President Steve Simpson, MD, FCCP.
It is also essential that those who cannot travel can still avail themselves of the engaging and interactive learning offered at the CHEST conference. Everyone – whether online or in-person – will be able to experience the meeting in real-time, including expert faculty presentations, simulated learning experiences, gaming, and more.
What to expect
Through bite-sized, immersive learning, experts in the field will cover the latest updates in pulmonary, critical care, and sleep medicine. CHEST 2021 offers you the opportunity to learn from a diverse set of knowledgeable educators representing different viewpoints and experiences.
Team-based learning is an indispensable component of the annual meeting. The activities support collaborative discovery and help you build relationships with your peers. Known for its development of simulation courses, at CHEST 2021, you can take part in the latest in “hands-on” learning. In addition, gaming will allow for friendly competition among colleagues, whether playing from home or on-site.
Getting involved
Make your mark by submitting your original abstracts and case reports to be presented at CHEST 2021. Because of the past year’s challenges, new discoveries were made in the treatment and approaches to managing chest medicine diseases. This work is important and will inform the way patients receive care in the future.
Showcase COVID-19 research, among other topics you are working on, for a chance to share your findings with colleagues, gain feedback from expert faculty, collaborate with other professionals in the field, and expand your professional portfolio. The deadline to submit is April 28. [link]
Keeping safe
It’s been a long time since in-person conferences were possible. CHEST is closely monitoring the status of the pandemic throughout the planning process. The Orange County Convention Center was selected because the venue is large enough to support social distancing. The CHEST team is establishing protocols that limit the number of individuals in a space, promote good traffic flow, require the wearing of masks, and other safety measures. All on-site participants and CHEST support staff will be required to attest to having received a COVID-19 vaccination to attend.
Continue to watch for more information. Registration for CHEST 2021 will open in May. We’ve missed you, and we look forward to seeing you in Orlando, Florida, October 17-20.
Disaster response and global health. Interstitial and diffuse lung disease. Practice operations. Transplant. Women’s lung health.
Disaster response and global health
One step forward, two back…
No adult alive today will live to see global gender parity. The 2020 World Economic Forum Global Gender Gap Report, published December 2019, assessed four dimensions of gender inequality – health, economic opportunities, educational advancement, and political empowerment.
The report stated that despite some advances, overall global gender parity would not be reached for 99 years. The gender gap is not solely a developing nation’s problem. The US standing as the 51st in gender parity fell to 53rd during the previous 2-year period. And these numbers were before Covid COVID-19.
Disasters, including pandemics, negatively affect female subjects disproportionately. Covid COVID-19 has unmasked and exacerbated both gender and minority disparity. Global health care workers (HCW) are overwhelmingly female, exposing them to a higher risk of contagion. This risk was exceptionally high among Black, Asian, and minority ethnic HCW (Nguyen et al. Lancet Public Health. 2020;5[9]:E475). The gender pay gap, where women are paid 80% of their male counterparts and women of color make 63%, has led to a greater financial burden among female HCW during Covid COVID-19. Women, including HCW, provide the majority of the unpaid work, i.e., childcare, elder care, and home care. 2020 saw an unprecedented loss of women in the workplace, including health care. Both clinical practice and research have been affected. The long- term effect on women HCW careers is unknown at present. Global gross domestic product growth loss due to this decline in the female workforce is estimated at 1 trillion USD over the next decade.
Disaster and gender parity are entwined. Covid COVID-19 has revealed the persistence of inequalities that nees to be considered in future disaster planning.
Mary Jane Reed, MD, FCCP
Steering Committee Ex-Officio
Interstitial and diffuse lung disease
Emergence and benefits of home monitoring and telemedicine for patients with ILD
Patients with interstitial lung disease (ILD) require regular monitoring with outpatient clinic visits and pulmonary function tests.
The emergence of COVID-19 forced an unprecedented transition to telemedicine and a new reliance on home monitoring. Home spirometry enables quick detection of rapidly progressive disease and is more sensitive than hospital-based spirometry in predicting prognosis (Russel, et al. Am J Respir Crit Care Med. 2016;194[8]:989). Patients with idiopathic pulmonary fibrosis randomized to a home monitoring program had improved psychological wellbeing and higher patient satisfaction with individually tailored treatment decisions (Moor, et al. Am J Respir Crit Care Med. 2020;202[3]:393). However, there are some inaccuracies in home monitoring. For instance, pulse oximetry is less reliable in African American patients receiving supplemental oxygen (Sjoding, et al. N Engl J Med. 2020;383:2477). It is critical to protect ILD patients from potential COVID-19 exposure given the high risk of serious complications. Telemedicine should be offered to all patients and may actually increase access to care in ILD patients, a population with disabling dyspnea and supplemental oxygen needs that requires specialist care unavailable in many geographic regions. African American patients, those older than 65, and patients with lower socioeconomic status are less willing to engage in videoconferencing (Fischer, et al. JAMA Netw Open. 2020;3[10]:e2022302). It is essential that telephone visits be offered to minimize disparities in access to care. Many telemedicine platforms enable caregivers and family members to attend visits from separate locations and provide a unique opportunity to address advance care planning. In-person visits should be arranged for patients with no access to internet or telephone or those with poor medical literacy or insufficient social support to conduct a productive remote visit. Telemedicine and home monitoring have proved invaluable during the COVID-19 pandemic and have the potential to continually increase access to and quality of care.
Rebecca Anna Gersten, MD
Steering Committee Member
Practice operations
Use of media platforms to eliminate the COVID-19 infodemic
We were shocked when we read a tweet in December 2020 from a health care worker stating, “My biggest concern is the lack of data and the quick development time. Feels like we are a bunch of guinea pigs” in reference to the new COVID-19 vaccine.
I reflected back on the last pandemic in 2009, H1N1, and remembered when the new vaccine developed in 174 days was first released to pregnant women and children after phase 3 trials. How did we get here? What do we do to fix it?
This misinformation is labeled as the “COVID-19 infodemic.” In the last year, we have seen the media, more specifically social platforms, quickly spread medical misinformation. In the book “Made to Stick: Why Some Ideas Survive and Some Die,” the authors described core elements that make an idea “sticky.” Use of those exact same sticky techniques can be used to circulate accurate information and to halt the spread of this infodemic. Although, numerous media companies, including Twitter, are making an effort to remove the false content from their platforms, their efforts require a lengthy process and are delayed. Therefore, it is crucial for the public health figures and community at large in partnership with various national organizations to establish a robust connection with the social platforms in a dynamic and timely fashion to help spread the verified information across social media, digital and traditional media outlets.
The UN has launched an initiate called “Verified.” This is a worldwide effort to help individuals spread reliable information regarding COVID-19 to their friends and families via social platforms as various media platforms and businesses have partnered with Verified. Also, we encourage our members to access the CHEST COVID-19 resource center and benefit from the various clinical and practice management tools along with validated patient information materials.
Roozera Khan, DO, FCCP
Steering Committee Member
Humayun Anjum, MD, FCCP
Chair
References
1. The Lancet Infectious Diseases-Editorial. The COVID-19 infodemic. Lancet Infect Dis. 2020;20(8):875.
2. Tangcharoensathien V, et al. Framework for managing the COVID-19 infodemic: methods and results of an online, crowdsourced WHO technical consultation. J Med Internet Res. 2020;22e19659.
3. Verified. https://shareverified.com/en/about. Accessed Feb 18, 2021.
Transplant
COVID-19 + lung transplant
The COVID-19 pandemic has created a dilemma for lung transplantation, with a new group of patients with refractory respiratory failure secondary to the viral illness. As transplant centers worldwide receive referrals for COVID-19 related respiratory failure, information regarding evaluation, listing, and posttransplant care continues to be published, but further research will be needed to care for this complex population.
The first lung transplant for COVID-19 in the United States occurred at Northwestern Hospital on June 5th, 2020,and was publicized for its innovativeness. Information from their three lung transplants completed thus far includes information regarding pathologic findings of the explanted lung tissue; pulmonary fibrosis was the dominant feature, suggesting COVID-19-induced acute respiratory distress syndrome with prolonged time supported by mechanical support may only be survivable with the use of lung transplant (Bharat, et al. Sci Transl Med. 2020;12(574):eabe4282).
Lung transplant in the setting of COVID-19 fibrosis increases surgical complexity as well, with case reports of dense adhesions and distortion of regular surgical planes (Bharat, et al. Sci. Transl. Med. 2020; Lang, et al. Lancet Respir Med. 2020;8:1057). Recognizing the difficulty with deciding to use transplantation after an infectious disease, The International Society for Heart and Lung Transplant (ISHLT) has created guidelines regarding indications for transplantation (ISHLT.org). Continued research will be necessary to identify those at the highest likelihood for success from transplantation, preparation for the increased complexity, and long-term outcomes. Further information is available in a CHEST webinar titled “Lung Transplantation in the Era of COVID-19” .
Clauden Louis, MD
Grant Turner, MD
Fellows-in-Training NetWork Members
Women’s lung health
Pregnancy in cystic fibrosis
The newest in the line of modulator therapy, Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is expected to improve life expectancy and quality of life for patients with cystic fibrosis (CF). This evolution in therapy will shape how providers care for their patients, particularly women of reproductive age. Conventionally, women with significantly impaired lung function due to CF have been advised to avoid pregnancy due to potential complications for mother and baby. It is likely that now, with improved lung function while receiving Trikafta, more women will feel better equipped to attempt pregnancy.
There are several considerations in this setting, including the need for careful drug safety and monitoring, creating a plan of action for possible decline in lung function while off certain CF-related medications, and counseling on drug interactions during lactation. In our experience with women becoming pregnant while receiving Trikafta or contemplating pregnancy, all have opted to discontinue modulator therapy with declines in lung function. Trikafta does not report teratogenicity based on animal studies of the individual components of the drug; however, ivacaftor is known to cause impairment in fertility and reproductive indices, including nonviable embryos and implantation failure in a rat model at five times the maximum recommended human dose, dosed prior to and during early embryogenesis. Small mammal models have decreased birth weight at high doses of elexacaftor, tezacaftor and ivacaftor administered individually. There is evidence of placental transfer of ivacaftor and breast milk concentrations of tezacaftor and ivacaftor are higher than plasma concentrations in rats. There are no human data in parturient or lactating women or infants. Three women became pregnant during the phase 3 clinical study of Trikafta, one with elective termination, one pregnancy was carried to full term with normal birth outcome, and one ended in a spontaneous abortion, which was deemed not to be related to the study drug. Translating this information into recommendations for patients has important implications.
Debasree Banerjee, MD, MS
Steering Committee Member
Disaster response and global health
One step forward, two back…
No adult alive today will live to see global gender parity. The 2020 World Economic Forum Global Gender Gap Report, published December 2019, assessed four dimensions of gender inequality – health, economic opportunities, educational advancement, and political empowerment.
The report stated that despite some advances, overall global gender parity would not be reached for 99 years. The gender gap is not solely a developing nation’s problem. The US standing as the 51st in gender parity fell to 53rd during the previous 2-year period. And these numbers were before Covid COVID-19.
Disasters, including pandemics, negatively affect female subjects disproportionately. Covid COVID-19 has unmasked and exacerbated both gender and minority disparity. Global health care workers (HCW) are overwhelmingly female, exposing them to a higher risk of contagion. This risk was exceptionally high among Black, Asian, and minority ethnic HCW (Nguyen et al. Lancet Public Health. 2020;5[9]:E475). The gender pay gap, where women are paid 80% of their male counterparts and women of color make 63%, has led to a greater financial burden among female HCW during Covid COVID-19. Women, including HCW, provide the majority of the unpaid work, i.e., childcare, elder care, and home care. 2020 saw an unprecedented loss of women in the workplace, including health care. Both clinical practice and research have been affected. The long- term effect on women HCW careers is unknown at present. Global gross domestic product growth loss due to this decline in the female workforce is estimated at 1 trillion USD over the next decade.
Disaster and gender parity are entwined. Covid COVID-19 has revealed the persistence of inequalities that nees to be considered in future disaster planning.
Mary Jane Reed, MD, FCCP
Steering Committee Ex-Officio
Interstitial and diffuse lung disease
Emergence and benefits of home monitoring and telemedicine for patients with ILD
Patients with interstitial lung disease (ILD) require regular monitoring with outpatient clinic visits and pulmonary function tests.
The emergence of COVID-19 forced an unprecedented transition to telemedicine and a new reliance on home monitoring. Home spirometry enables quick detection of rapidly progressive disease and is more sensitive than hospital-based spirometry in predicting prognosis (Russel, et al. Am J Respir Crit Care Med. 2016;194[8]:989). Patients with idiopathic pulmonary fibrosis randomized to a home monitoring program had improved psychological wellbeing and higher patient satisfaction with individually tailored treatment decisions (Moor, et al. Am J Respir Crit Care Med. 2020;202[3]:393). However, there are some inaccuracies in home monitoring. For instance, pulse oximetry is less reliable in African American patients receiving supplemental oxygen (Sjoding, et al. N Engl J Med. 2020;383:2477). It is critical to protect ILD patients from potential COVID-19 exposure given the high risk of serious complications. Telemedicine should be offered to all patients and may actually increase access to care in ILD patients, a population with disabling dyspnea and supplemental oxygen needs that requires specialist care unavailable in many geographic regions. African American patients, those older than 65, and patients with lower socioeconomic status are less willing to engage in videoconferencing (Fischer, et al. JAMA Netw Open. 2020;3[10]:e2022302). It is essential that telephone visits be offered to minimize disparities in access to care. Many telemedicine platforms enable caregivers and family members to attend visits from separate locations and provide a unique opportunity to address advance care planning. In-person visits should be arranged for patients with no access to internet or telephone or those with poor medical literacy or insufficient social support to conduct a productive remote visit. Telemedicine and home monitoring have proved invaluable during the COVID-19 pandemic and have the potential to continually increase access to and quality of care.
Rebecca Anna Gersten, MD
Steering Committee Member
Practice operations
Use of media platforms to eliminate the COVID-19 infodemic
We were shocked when we read a tweet in December 2020 from a health care worker stating, “My biggest concern is the lack of data and the quick development time. Feels like we are a bunch of guinea pigs” in reference to the new COVID-19 vaccine.
I reflected back on the last pandemic in 2009, H1N1, and remembered when the new vaccine developed in 174 days was first released to pregnant women and children after phase 3 trials. How did we get here? What do we do to fix it?
This misinformation is labeled as the “COVID-19 infodemic.” In the last year, we have seen the media, more specifically social platforms, quickly spread medical misinformation. In the book “Made to Stick: Why Some Ideas Survive and Some Die,” the authors described core elements that make an idea “sticky.” Use of those exact same sticky techniques can be used to circulate accurate information and to halt the spread of this infodemic. Although, numerous media companies, including Twitter, are making an effort to remove the false content from their platforms, their efforts require a lengthy process and are delayed. Therefore, it is crucial for the public health figures and community at large in partnership with various national organizations to establish a robust connection with the social platforms in a dynamic and timely fashion to help spread the verified information across social media, digital and traditional media outlets.
The UN has launched an initiate called “Verified.” This is a worldwide effort to help individuals spread reliable information regarding COVID-19 to their friends and families via social platforms as various media platforms and businesses have partnered with Verified. Also, we encourage our members to access the CHEST COVID-19 resource center and benefit from the various clinical and practice management tools along with validated patient information materials.
Roozera Khan, DO, FCCP
Steering Committee Member
Humayun Anjum, MD, FCCP
Chair
References
1. The Lancet Infectious Diseases-Editorial. The COVID-19 infodemic. Lancet Infect Dis. 2020;20(8):875.
2. Tangcharoensathien V, et al. Framework for managing the COVID-19 infodemic: methods and results of an online, crowdsourced WHO technical consultation. J Med Internet Res. 2020;22e19659.
3. Verified. https://shareverified.com/en/about. Accessed Feb 18, 2021.
Transplant
COVID-19 + lung transplant
The COVID-19 pandemic has created a dilemma for lung transplantation, with a new group of patients with refractory respiratory failure secondary to the viral illness. As transplant centers worldwide receive referrals for COVID-19 related respiratory failure, information regarding evaluation, listing, and posttransplant care continues to be published, but further research will be needed to care for this complex population.
The first lung transplant for COVID-19 in the United States occurred at Northwestern Hospital on June 5th, 2020,and was publicized for its innovativeness. Information from their three lung transplants completed thus far includes information regarding pathologic findings of the explanted lung tissue; pulmonary fibrosis was the dominant feature, suggesting COVID-19-induced acute respiratory distress syndrome with prolonged time supported by mechanical support may only be survivable with the use of lung transplant (Bharat, et al. Sci Transl Med. 2020;12(574):eabe4282).
Lung transplant in the setting of COVID-19 fibrosis increases surgical complexity as well, with case reports of dense adhesions and distortion of regular surgical planes (Bharat, et al. Sci. Transl. Med. 2020; Lang, et al. Lancet Respir Med. 2020;8:1057). Recognizing the difficulty with deciding to use transplantation after an infectious disease, The International Society for Heart and Lung Transplant (ISHLT) has created guidelines regarding indications for transplantation (ISHLT.org). Continued research will be necessary to identify those at the highest likelihood for success from transplantation, preparation for the increased complexity, and long-term outcomes. Further information is available in a CHEST webinar titled “Lung Transplantation in the Era of COVID-19” .
Clauden Louis, MD
Grant Turner, MD
Fellows-in-Training NetWork Members
Women’s lung health
Pregnancy in cystic fibrosis
The newest in the line of modulator therapy, Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is expected to improve life expectancy and quality of life for patients with cystic fibrosis (CF). This evolution in therapy will shape how providers care for their patients, particularly women of reproductive age. Conventionally, women with significantly impaired lung function due to CF have been advised to avoid pregnancy due to potential complications for mother and baby. It is likely that now, with improved lung function while receiving Trikafta, more women will feel better equipped to attempt pregnancy.
There are several considerations in this setting, including the need for careful drug safety and monitoring, creating a plan of action for possible decline in lung function while off certain CF-related medications, and counseling on drug interactions during lactation. In our experience with women becoming pregnant while receiving Trikafta or contemplating pregnancy, all have opted to discontinue modulator therapy with declines in lung function. Trikafta does not report teratogenicity based on animal studies of the individual components of the drug; however, ivacaftor is known to cause impairment in fertility and reproductive indices, including nonviable embryos and implantation failure in a rat model at five times the maximum recommended human dose, dosed prior to and during early embryogenesis. Small mammal models have decreased birth weight at high doses of elexacaftor, tezacaftor and ivacaftor administered individually. There is evidence of placental transfer of ivacaftor and breast milk concentrations of tezacaftor and ivacaftor are higher than plasma concentrations in rats. There are no human data in parturient or lactating women or infants. Three women became pregnant during the phase 3 clinical study of Trikafta, one with elective termination, one pregnancy was carried to full term with normal birth outcome, and one ended in a spontaneous abortion, which was deemed not to be related to the study drug. Translating this information into recommendations for patients has important implications.
Debasree Banerjee, MD, MS
Steering Committee Member
Disaster response and global health
One step forward, two back…
No adult alive today will live to see global gender parity. The 2020 World Economic Forum Global Gender Gap Report, published December 2019, assessed four dimensions of gender inequality – health, economic opportunities, educational advancement, and political empowerment.
The report stated that despite some advances, overall global gender parity would not be reached for 99 years. The gender gap is not solely a developing nation’s problem. The US standing as the 51st in gender parity fell to 53rd during the previous 2-year period. And these numbers were before Covid COVID-19.
Disasters, including pandemics, negatively affect female subjects disproportionately. Covid COVID-19 has unmasked and exacerbated both gender and minority disparity. Global health care workers (HCW) are overwhelmingly female, exposing them to a higher risk of contagion. This risk was exceptionally high among Black, Asian, and minority ethnic HCW (Nguyen et al. Lancet Public Health. 2020;5[9]:E475). The gender pay gap, where women are paid 80% of their male counterparts and women of color make 63%, has led to a greater financial burden among female HCW during Covid COVID-19. Women, including HCW, provide the majority of the unpaid work, i.e., childcare, elder care, and home care. 2020 saw an unprecedented loss of women in the workplace, including health care. Both clinical practice and research have been affected. The long- term effect on women HCW careers is unknown at present. Global gross domestic product growth loss due to this decline in the female workforce is estimated at 1 trillion USD over the next decade.
Disaster and gender parity are entwined. Covid COVID-19 has revealed the persistence of inequalities that nees to be considered in future disaster planning.
Mary Jane Reed, MD, FCCP
Steering Committee Ex-Officio
Interstitial and diffuse lung disease
Emergence and benefits of home monitoring and telemedicine for patients with ILD
Patients with interstitial lung disease (ILD) require regular monitoring with outpatient clinic visits and pulmonary function tests.
The emergence of COVID-19 forced an unprecedented transition to telemedicine and a new reliance on home monitoring. Home spirometry enables quick detection of rapidly progressive disease and is more sensitive than hospital-based spirometry in predicting prognosis (Russel, et al. Am J Respir Crit Care Med. 2016;194[8]:989). Patients with idiopathic pulmonary fibrosis randomized to a home monitoring program had improved psychological wellbeing and higher patient satisfaction with individually tailored treatment decisions (Moor, et al. Am J Respir Crit Care Med. 2020;202[3]:393). However, there are some inaccuracies in home monitoring. For instance, pulse oximetry is less reliable in African American patients receiving supplemental oxygen (Sjoding, et al. N Engl J Med. 2020;383:2477). It is critical to protect ILD patients from potential COVID-19 exposure given the high risk of serious complications. Telemedicine should be offered to all patients and may actually increase access to care in ILD patients, a population with disabling dyspnea and supplemental oxygen needs that requires specialist care unavailable in many geographic regions. African American patients, those older than 65, and patients with lower socioeconomic status are less willing to engage in videoconferencing (Fischer, et al. JAMA Netw Open. 2020;3[10]:e2022302). It is essential that telephone visits be offered to minimize disparities in access to care. Many telemedicine platforms enable caregivers and family members to attend visits from separate locations and provide a unique opportunity to address advance care planning. In-person visits should be arranged for patients with no access to internet or telephone or those with poor medical literacy or insufficient social support to conduct a productive remote visit. Telemedicine and home monitoring have proved invaluable during the COVID-19 pandemic and have the potential to continually increase access to and quality of care.
Rebecca Anna Gersten, MD
Steering Committee Member
Practice operations
Use of media platforms to eliminate the COVID-19 infodemic
We were shocked when we read a tweet in December 2020 from a health care worker stating, “My biggest concern is the lack of data and the quick development time. Feels like we are a bunch of guinea pigs” in reference to the new COVID-19 vaccine.
I reflected back on the last pandemic in 2009, H1N1, and remembered when the new vaccine developed in 174 days was first released to pregnant women and children after phase 3 trials. How did we get here? What do we do to fix it?
This misinformation is labeled as the “COVID-19 infodemic.” In the last year, we have seen the media, more specifically social platforms, quickly spread medical misinformation. In the book “Made to Stick: Why Some Ideas Survive and Some Die,” the authors described core elements that make an idea “sticky.” Use of those exact same sticky techniques can be used to circulate accurate information and to halt the spread of this infodemic. Although, numerous media companies, including Twitter, are making an effort to remove the false content from their platforms, their efforts require a lengthy process and are delayed. Therefore, it is crucial for the public health figures and community at large in partnership with various national organizations to establish a robust connection with the social platforms in a dynamic and timely fashion to help spread the verified information across social media, digital and traditional media outlets.
The UN has launched an initiate called “Verified.” This is a worldwide effort to help individuals spread reliable information regarding COVID-19 to their friends and families via social platforms as various media platforms and businesses have partnered with Verified. Also, we encourage our members to access the CHEST COVID-19 resource center and benefit from the various clinical and practice management tools along with validated patient information materials.
Roozera Khan, DO, FCCP
Steering Committee Member
Humayun Anjum, MD, FCCP
Chair
References
1. The Lancet Infectious Diseases-Editorial. The COVID-19 infodemic. Lancet Infect Dis. 2020;20(8):875.
2. Tangcharoensathien V, et al. Framework for managing the COVID-19 infodemic: methods and results of an online, crowdsourced WHO technical consultation. J Med Internet Res. 2020;22e19659.
3. Verified. https://shareverified.com/en/about. Accessed Feb 18, 2021.
Transplant
COVID-19 + lung transplant
The COVID-19 pandemic has created a dilemma for lung transplantation, with a new group of patients with refractory respiratory failure secondary to the viral illness. As transplant centers worldwide receive referrals for COVID-19 related respiratory failure, information regarding evaluation, listing, and posttransplant care continues to be published, but further research will be needed to care for this complex population.
The first lung transplant for COVID-19 in the United States occurred at Northwestern Hospital on June 5th, 2020,and was publicized for its innovativeness. Information from their three lung transplants completed thus far includes information regarding pathologic findings of the explanted lung tissue; pulmonary fibrosis was the dominant feature, suggesting COVID-19-induced acute respiratory distress syndrome with prolonged time supported by mechanical support may only be survivable with the use of lung transplant (Bharat, et al. Sci Transl Med. 2020;12(574):eabe4282).
Lung transplant in the setting of COVID-19 fibrosis increases surgical complexity as well, with case reports of dense adhesions and distortion of regular surgical planes (Bharat, et al. Sci. Transl. Med. 2020; Lang, et al. Lancet Respir Med. 2020;8:1057). Recognizing the difficulty with deciding to use transplantation after an infectious disease, The International Society for Heart and Lung Transplant (ISHLT) has created guidelines regarding indications for transplantation (ISHLT.org). Continued research will be necessary to identify those at the highest likelihood for success from transplantation, preparation for the increased complexity, and long-term outcomes. Further information is available in a CHEST webinar titled “Lung Transplantation in the Era of COVID-19” .
Clauden Louis, MD
Grant Turner, MD
Fellows-in-Training NetWork Members
Women’s lung health
Pregnancy in cystic fibrosis
The newest in the line of modulator therapy, Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is expected to improve life expectancy and quality of life for patients with cystic fibrosis (CF). This evolution in therapy will shape how providers care for their patients, particularly women of reproductive age. Conventionally, women with significantly impaired lung function due to CF have been advised to avoid pregnancy due to potential complications for mother and baby. It is likely that now, with improved lung function while receiving Trikafta, more women will feel better equipped to attempt pregnancy.
There are several considerations in this setting, including the need for careful drug safety and monitoring, creating a plan of action for possible decline in lung function while off certain CF-related medications, and counseling on drug interactions during lactation. In our experience with women becoming pregnant while receiving Trikafta or contemplating pregnancy, all have opted to discontinue modulator therapy with declines in lung function. Trikafta does not report teratogenicity based on animal studies of the individual components of the drug; however, ivacaftor is known to cause impairment in fertility and reproductive indices, including nonviable embryos and implantation failure in a rat model at five times the maximum recommended human dose, dosed prior to and during early embryogenesis. Small mammal models have decreased birth weight at high doses of elexacaftor, tezacaftor and ivacaftor administered individually. There is evidence of placental transfer of ivacaftor and breast milk concentrations of tezacaftor and ivacaftor are higher than plasma concentrations in rats. There are no human data in parturient or lactating women or infants. Three women became pregnant during the phase 3 clinical study of Trikafta, one with elective termination, one pregnancy was carried to full term with normal birth outcome, and one ended in a spontaneous abortion, which was deemed not to be related to the study drug. Translating this information into recommendations for patients has important implications.
Debasree Banerjee, MD, MS
Steering Committee Member
President’s report
As I write, it is 1 degree Fahrenheit and dreary in Kansas City, where I live. That’s minus 17 degrees Celsius for many of you. I hope that it is cheerier and bordering on springtime when you’re reading. You’ll understand, though, why I say Happy 2021! 2020 was a humdinger in many ways.
One of those ways, of course, was the COVID-19 pandemic, which wrought so many things – face masks, social distancing, steep learning curves, over 300,000 excess deaths, and new vaccines. For CHEST, it meant that two of our most important educational opportunities of the year, board review and the annual meeting, were held virtually. Dr. Levine has already written about the board reviews, so I’ll focus on the annual meeting, held in late October.
In many ways, the meeting was a success. We had over 6,800 attendees. There were 88 live online sessions, 22 that were semi-live, and 160 prerecorded sessions. For presenters, this was simultaneously both easy and difficult. They had to ensure that their recording equipment and their Internet access were of sufficient quality, and if prerecorded, the sessions had to be finished weeks ahead of time. But the presentations could be given from presenters’ homes or from their normal work offices. For attendees, the ability for nonsimultaneous playback allowed for fitting the meeting into a work-life schedule. In fact, at least one friend related that he watched sessions with a grandchild on his lap. However, it meant a lack of opportunities to ask clarifying questions of the presenters, which is a common activity at the end of a session, and the opportunity to see and catch up with old friends and colleagues was missing. Simulations, of course, could not be hands-on, but virtual educational games matured significantly. The satisfaction scores from both attendees and faculty were good, if slightly below our usual scores for live meetings. They told us that we all prefer our in-person meetings, but that content is deliverable and receivable in an online format. Overall, we have to consider the CHEST 2020 online platform to be a successful endeavor.
Which brings me to our plans for future meetings. The Board of Regents discussed the alternatives for CHEST 2021. Should we hold a live meeting in Vancouver, as planned? Should we hold another online meeting like the one we just discussed? None of us has the crystal ball that tells us exactly how COVID-19 is going to develop. We don’t know exactly how many people will be vaccinated either north or south of the U.S.-Canada border. While those of us who care for patients in the United States have had the opportunity to be vaccinated, we don’t know if the professional staff from CHEST headquarters who travel to the annual meeting will be vaccinated, even though that prospect is currently looking very reasonable. We don’t know if the Canadian government will be allowing U.S. residents to visit Canada without quarantine. There are just quite a few things that we can’t know. However, convention centers need to know if we will be there, and we needed to decide.
In the end, a couple of things swayed us—the unexpected availability of a U.S. convention center and uncertainty about travel to Canada. We are planning to hold CHEST 2021 in Orlando, Florida, during our usual late October time frame. CHEST 2021 is slated to be the first in-person pulmonary, critical care, and sleep conference to be held in the United States in 2 years. The Executive Program Committee has met, and program selections have been made. Very soon, invitations will go to our prospective faculty, and we will be underway. We are planning CHEST 2021 as what we call a “hybrid” meeting, a meeting that will provide an excellent experience whether one attends in person at the Orlando Convention Center or partakes of the meeting from home. Some sessions will be broadcast live and others will be prerecorded. Needless to say, the experience will not be equal for in-person and at-home learners, but it will be equitable. Regardless of how you choose to partake, CHEST 2021 will have excellent content to suit your needs. This plan also allows us the ability to convert to a fully online meeting, should the COVID-19 circumstances dictate that we must. Having sat in on the program committee meetings, I am excited about what we have to offer. So, dig around and find your old mouse ears or your red forehead scar. CHEST 2021 will be a dynamite experience for us all to share.
Our board review sessions, which are also among the most highly valued of CHEST activities, will be different out of necessity. Again, decisions had to be made many months ahead of time, and we have chosen to hold our board reviews online again this year. COVID-19 uncertainties certainly play into our decision to not put attendees in a room together. However, the ability to play and replay, slow down and speed up video content, and ability to watch any session any time are all well suited to reviewing for an examination. We think this is the appropriate decision for 2021, but we may be back together again for future sessions. Frankly, we are listening to hear which format our attendees like more. And, we are plotting how to make the online platform review even better.
The Board of Regents has been hard at work on a lot of fronts, but I want to focus on one of them, for now. It is important to the Board of Regents and to me, personally, that CHEST be the single most inclusive and diverse professional medical society, bar none. It is of utmost importance that we remove any barriers that might have inadvertently been put into place that would hamper the success of any of our members or their patients. In other words, we hope to find any implicit biases in attitude and behavior and to illuminate and remedy them. We have begun the process by focusing on what CHEST is all about – making a difference with our patients and corporate self and being an inclusive and diverse professional organization.
We believe that we must look at ourselves in three separate, but related, ways. We must examine our patient-facing side and the ways in which we help our members to serve their patients. We must examine our headquarters and our hiring, working, and promoting practices to ensure an inclusive and welcoming environment for the staff who do our day to day business. Finally, we must examine ourselves and our member-based organization, to ensure that all can participate freely in CHEST opportunities and, for those who aspire to lead our organization, to ensure that there are no implicit biases that hold them back.
We began the process with a series of regional listening sessions across the United States, sponsored by the CHEST Foundation, in which we heard from both patients and community leaders of color. We learned of challenges that our patients face in accessing care, communicating with their doctors, and obtaining the medications they need for their illness. Our professional staff has organized an anti-racism task force and is working to ensure that we can be proud of a diverse and inclusive work environment. For our members, we have held two board development sessions, so that our Board of Regents can examine us and our attitudes toward race and toward inclusiveness in our organization. We will soon be holding a listening session with CHEST members of color with the express purpose of allowing those of us who are not persons of color to better understand the challenges faced by our members and to understand where organizational changes could be necessary to help make their professional lives better. As a long time CHEST member, I believe that CHEST is not purposefully exclusive of anyone. We are, nevertheless, a part of the larger fabric of society, and because of that, we are subject to having implicit biases and practices as an organization. Our best path to be aware of them and to deal with them is to hear from our members who experience them, and we shall.
I will end on a note that is somber but important. In the past year, we have all lost friends and colleagues with whom we worked side by side, to COVID-19. Many of them have been CHEST members. Because of the pandemic, we have often not been able to mourn those we have cared about in the same ways that we normally would, in the company of friends and family. Yet, it is important for us to remember our colleagues and to share our memories. So, we established CHEST Remembers, a memorial wall on the CHEST website where we can post the news of our friends’ passing, along with our remembrances of them. If your friend or colleague has died of COVID-19, please feel free to share with the CHEST community. You can find the link to do that at www.chestnet.org.
As I write, it is 1 degree Fahrenheit and dreary in Kansas City, where I live. That’s minus 17 degrees Celsius for many of you. I hope that it is cheerier and bordering on springtime when you’re reading. You’ll understand, though, why I say Happy 2021! 2020 was a humdinger in many ways.
One of those ways, of course, was the COVID-19 pandemic, which wrought so many things – face masks, social distancing, steep learning curves, over 300,000 excess deaths, and new vaccines. For CHEST, it meant that two of our most important educational opportunities of the year, board review and the annual meeting, were held virtually. Dr. Levine has already written about the board reviews, so I’ll focus on the annual meeting, held in late October.
In many ways, the meeting was a success. We had over 6,800 attendees. There were 88 live online sessions, 22 that were semi-live, and 160 prerecorded sessions. For presenters, this was simultaneously both easy and difficult. They had to ensure that their recording equipment and their Internet access were of sufficient quality, and if prerecorded, the sessions had to be finished weeks ahead of time. But the presentations could be given from presenters’ homes or from their normal work offices. For attendees, the ability for nonsimultaneous playback allowed for fitting the meeting into a work-life schedule. In fact, at least one friend related that he watched sessions with a grandchild on his lap. However, it meant a lack of opportunities to ask clarifying questions of the presenters, which is a common activity at the end of a session, and the opportunity to see and catch up with old friends and colleagues was missing. Simulations, of course, could not be hands-on, but virtual educational games matured significantly. The satisfaction scores from both attendees and faculty were good, if slightly below our usual scores for live meetings. They told us that we all prefer our in-person meetings, but that content is deliverable and receivable in an online format. Overall, we have to consider the CHEST 2020 online platform to be a successful endeavor.
Which brings me to our plans for future meetings. The Board of Regents discussed the alternatives for CHEST 2021. Should we hold a live meeting in Vancouver, as planned? Should we hold another online meeting like the one we just discussed? None of us has the crystal ball that tells us exactly how COVID-19 is going to develop. We don’t know exactly how many people will be vaccinated either north or south of the U.S.-Canada border. While those of us who care for patients in the United States have had the opportunity to be vaccinated, we don’t know if the professional staff from CHEST headquarters who travel to the annual meeting will be vaccinated, even though that prospect is currently looking very reasonable. We don’t know if the Canadian government will be allowing U.S. residents to visit Canada without quarantine. There are just quite a few things that we can’t know. However, convention centers need to know if we will be there, and we needed to decide.
In the end, a couple of things swayed us—the unexpected availability of a U.S. convention center and uncertainty about travel to Canada. We are planning to hold CHEST 2021 in Orlando, Florida, during our usual late October time frame. CHEST 2021 is slated to be the first in-person pulmonary, critical care, and sleep conference to be held in the United States in 2 years. The Executive Program Committee has met, and program selections have been made. Very soon, invitations will go to our prospective faculty, and we will be underway. We are planning CHEST 2021 as what we call a “hybrid” meeting, a meeting that will provide an excellent experience whether one attends in person at the Orlando Convention Center or partakes of the meeting from home. Some sessions will be broadcast live and others will be prerecorded. Needless to say, the experience will not be equal for in-person and at-home learners, but it will be equitable. Regardless of how you choose to partake, CHEST 2021 will have excellent content to suit your needs. This plan also allows us the ability to convert to a fully online meeting, should the COVID-19 circumstances dictate that we must. Having sat in on the program committee meetings, I am excited about what we have to offer. So, dig around and find your old mouse ears or your red forehead scar. CHEST 2021 will be a dynamite experience for us all to share.
Our board review sessions, which are also among the most highly valued of CHEST activities, will be different out of necessity. Again, decisions had to be made many months ahead of time, and we have chosen to hold our board reviews online again this year. COVID-19 uncertainties certainly play into our decision to not put attendees in a room together. However, the ability to play and replay, slow down and speed up video content, and ability to watch any session any time are all well suited to reviewing for an examination. We think this is the appropriate decision for 2021, but we may be back together again for future sessions. Frankly, we are listening to hear which format our attendees like more. And, we are plotting how to make the online platform review even better.
The Board of Regents has been hard at work on a lot of fronts, but I want to focus on one of them, for now. It is important to the Board of Regents and to me, personally, that CHEST be the single most inclusive and diverse professional medical society, bar none. It is of utmost importance that we remove any barriers that might have inadvertently been put into place that would hamper the success of any of our members or their patients. In other words, we hope to find any implicit biases in attitude and behavior and to illuminate and remedy them. We have begun the process by focusing on what CHEST is all about – making a difference with our patients and corporate self and being an inclusive and diverse professional organization.
We believe that we must look at ourselves in three separate, but related, ways. We must examine our patient-facing side and the ways in which we help our members to serve their patients. We must examine our headquarters and our hiring, working, and promoting practices to ensure an inclusive and welcoming environment for the staff who do our day to day business. Finally, we must examine ourselves and our member-based organization, to ensure that all can participate freely in CHEST opportunities and, for those who aspire to lead our organization, to ensure that there are no implicit biases that hold them back.
We began the process with a series of regional listening sessions across the United States, sponsored by the CHEST Foundation, in which we heard from both patients and community leaders of color. We learned of challenges that our patients face in accessing care, communicating with their doctors, and obtaining the medications they need for their illness. Our professional staff has organized an anti-racism task force and is working to ensure that we can be proud of a diverse and inclusive work environment. For our members, we have held two board development sessions, so that our Board of Regents can examine us and our attitudes toward race and toward inclusiveness in our organization. We will soon be holding a listening session with CHEST members of color with the express purpose of allowing those of us who are not persons of color to better understand the challenges faced by our members and to understand where organizational changes could be necessary to help make their professional lives better. As a long time CHEST member, I believe that CHEST is not purposefully exclusive of anyone. We are, nevertheless, a part of the larger fabric of society, and because of that, we are subject to having implicit biases and practices as an organization. Our best path to be aware of them and to deal with them is to hear from our members who experience them, and we shall.
I will end on a note that is somber but important. In the past year, we have all lost friends and colleagues with whom we worked side by side, to COVID-19. Many of them have been CHEST members. Because of the pandemic, we have often not been able to mourn those we have cared about in the same ways that we normally would, in the company of friends and family. Yet, it is important for us to remember our colleagues and to share our memories. So, we established CHEST Remembers, a memorial wall on the CHEST website where we can post the news of our friends’ passing, along with our remembrances of them. If your friend or colleague has died of COVID-19, please feel free to share with the CHEST community. You can find the link to do that at www.chestnet.org.
As I write, it is 1 degree Fahrenheit and dreary in Kansas City, where I live. That’s minus 17 degrees Celsius for many of you. I hope that it is cheerier and bordering on springtime when you’re reading. You’ll understand, though, why I say Happy 2021! 2020 was a humdinger in many ways.
One of those ways, of course, was the COVID-19 pandemic, which wrought so many things – face masks, social distancing, steep learning curves, over 300,000 excess deaths, and new vaccines. For CHEST, it meant that two of our most important educational opportunities of the year, board review and the annual meeting, were held virtually. Dr. Levine has already written about the board reviews, so I’ll focus on the annual meeting, held in late October.
In many ways, the meeting was a success. We had over 6,800 attendees. There were 88 live online sessions, 22 that were semi-live, and 160 prerecorded sessions. For presenters, this was simultaneously both easy and difficult. They had to ensure that their recording equipment and their Internet access were of sufficient quality, and if prerecorded, the sessions had to be finished weeks ahead of time. But the presentations could be given from presenters’ homes or from their normal work offices. For attendees, the ability for nonsimultaneous playback allowed for fitting the meeting into a work-life schedule. In fact, at least one friend related that he watched sessions with a grandchild on his lap. However, it meant a lack of opportunities to ask clarifying questions of the presenters, which is a common activity at the end of a session, and the opportunity to see and catch up with old friends and colleagues was missing. Simulations, of course, could not be hands-on, but virtual educational games matured significantly. The satisfaction scores from both attendees and faculty were good, if slightly below our usual scores for live meetings. They told us that we all prefer our in-person meetings, but that content is deliverable and receivable in an online format. Overall, we have to consider the CHEST 2020 online platform to be a successful endeavor.
Which brings me to our plans for future meetings. The Board of Regents discussed the alternatives for CHEST 2021. Should we hold a live meeting in Vancouver, as planned? Should we hold another online meeting like the one we just discussed? None of us has the crystal ball that tells us exactly how COVID-19 is going to develop. We don’t know exactly how many people will be vaccinated either north or south of the U.S.-Canada border. While those of us who care for patients in the United States have had the opportunity to be vaccinated, we don’t know if the professional staff from CHEST headquarters who travel to the annual meeting will be vaccinated, even though that prospect is currently looking very reasonable. We don’t know if the Canadian government will be allowing U.S. residents to visit Canada without quarantine. There are just quite a few things that we can’t know. However, convention centers need to know if we will be there, and we needed to decide.
In the end, a couple of things swayed us—the unexpected availability of a U.S. convention center and uncertainty about travel to Canada. We are planning to hold CHEST 2021 in Orlando, Florida, during our usual late October time frame. CHEST 2021 is slated to be the first in-person pulmonary, critical care, and sleep conference to be held in the United States in 2 years. The Executive Program Committee has met, and program selections have been made. Very soon, invitations will go to our prospective faculty, and we will be underway. We are planning CHEST 2021 as what we call a “hybrid” meeting, a meeting that will provide an excellent experience whether one attends in person at the Orlando Convention Center or partakes of the meeting from home. Some sessions will be broadcast live and others will be prerecorded. Needless to say, the experience will not be equal for in-person and at-home learners, but it will be equitable. Regardless of how you choose to partake, CHEST 2021 will have excellent content to suit your needs. This plan also allows us the ability to convert to a fully online meeting, should the COVID-19 circumstances dictate that we must. Having sat in on the program committee meetings, I am excited about what we have to offer. So, dig around and find your old mouse ears or your red forehead scar. CHEST 2021 will be a dynamite experience for us all to share.
Our board review sessions, which are also among the most highly valued of CHEST activities, will be different out of necessity. Again, decisions had to be made many months ahead of time, and we have chosen to hold our board reviews online again this year. COVID-19 uncertainties certainly play into our decision to not put attendees in a room together. However, the ability to play and replay, slow down and speed up video content, and ability to watch any session any time are all well suited to reviewing for an examination. We think this is the appropriate decision for 2021, but we may be back together again for future sessions. Frankly, we are listening to hear which format our attendees like more. And, we are plotting how to make the online platform review even better.
The Board of Regents has been hard at work on a lot of fronts, but I want to focus on one of them, for now. It is important to the Board of Regents and to me, personally, that CHEST be the single most inclusive and diverse professional medical society, bar none. It is of utmost importance that we remove any barriers that might have inadvertently been put into place that would hamper the success of any of our members or their patients. In other words, we hope to find any implicit biases in attitude and behavior and to illuminate and remedy them. We have begun the process by focusing on what CHEST is all about – making a difference with our patients and corporate self and being an inclusive and diverse professional organization.
We believe that we must look at ourselves in three separate, but related, ways. We must examine our patient-facing side and the ways in which we help our members to serve their patients. We must examine our headquarters and our hiring, working, and promoting practices to ensure an inclusive and welcoming environment for the staff who do our day to day business. Finally, we must examine ourselves and our member-based organization, to ensure that all can participate freely in CHEST opportunities and, for those who aspire to lead our organization, to ensure that there are no implicit biases that hold them back.
We began the process with a series of regional listening sessions across the United States, sponsored by the CHEST Foundation, in which we heard from both patients and community leaders of color. We learned of challenges that our patients face in accessing care, communicating with their doctors, and obtaining the medications they need for their illness. Our professional staff has organized an anti-racism task force and is working to ensure that we can be proud of a diverse and inclusive work environment. For our members, we have held two board development sessions, so that our Board of Regents can examine us and our attitudes toward race and toward inclusiveness in our organization. We will soon be holding a listening session with CHEST members of color with the express purpose of allowing those of us who are not persons of color to better understand the challenges faced by our members and to understand where organizational changes could be necessary to help make their professional lives better. As a long time CHEST member, I believe that CHEST is not purposefully exclusive of anyone. We are, nevertheless, a part of the larger fabric of society, and because of that, we are subject to having implicit biases and practices as an organization. Our best path to be aware of them and to deal with them is to hear from our members who experience them, and we shall.
I will end on a note that is somber but important. In the past year, we have all lost friends and colleagues with whom we worked side by side, to COVID-19. Many of them have been CHEST members. Because of the pandemic, we have often not been able to mourn those we have cared about in the same ways that we normally would, in the company of friends and family. Yet, it is important for us to remember our colleagues and to share our memories. So, we established CHEST Remembers, a memorial wall on the CHEST website where we can post the news of our friends’ passing, along with our remembrances of them. If your friend or colleague has died of COVID-19, please feel free to share with the CHEST community. You can find the link to do that at www.chestnet.org.
CHEST to offer research matching service
CHEST Analytics has announced its new resource for members interested in serving as investigators in industry-sponsored clinical trials.
The new program, CHEST Clinical Trials Solutions, will pair members who have indicated their interest in specific research topics with companies seeking investigators. According to CHEST President Steven Q. Simpson, MD, FCCP: “For members who would like to be involved in research and for companies that have defined distinct criteria for their studies, CHEST Analytics can pair qualifying parties to facilitate communication between researcher and sponsor. It’s a great way for young investigators to get started or accomplished members to share their experience while helping industry expedite introducing new products that improve patient care.” More information regarding enrollment will be available at info.chestnet.org/clinical-trials.
CHEST Analytics has announced its new resource for members interested in serving as investigators in industry-sponsored clinical trials.
The new program, CHEST Clinical Trials Solutions, will pair members who have indicated their interest in specific research topics with companies seeking investigators. According to CHEST President Steven Q. Simpson, MD, FCCP: “For members who would like to be involved in research and for companies that have defined distinct criteria for their studies, CHEST Analytics can pair qualifying parties to facilitate communication between researcher and sponsor. It’s a great way for young investigators to get started or accomplished members to share their experience while helping industry expedite introducing new products that improve patient care.” More information regarding enrollment will be available at info.chestnet.org/clinical-trials.
CHEST Analytics has announced its new resource for members interested in serving as investigators in industry-sponsored clinical trials.
The new program, CHEST Clinical Trials Solutions, will pair members who have indicated their interest in specific research topics with companies seeking investigators. According to CHEST President Steven Q. Simpson, MD, FCCP: “For members who would like to be involved in research and for companies that have defined distinct criteria for their studies, CHEST Analytics can pair qualifying parties to facilitate communication between researcher and sponsor. It’s a great way for young investigators to get started or accomplished members to share their experience while helping industry expedite introducing new products that improve patient care.” More information regarding enrollment will be available at info.chestnet.org/clinical-trials.
President-Designate: Doreen J. Addrizzo-Harris, MD, FCCP
Doreen J. Addrizzo-Harris, MD, FCCP, is a pulmonary/critical care physician with an extensive background in bronchiectasis and non-tuberculous mycobacterial infection and medical education.
Dr. Addrizzo-Harris is currently a Professor of Medicine at the NYU Grossman School of Medicine. She serves as the Associate Division Director for Clinical and Faculty Affairs, is the Director of the NYU Bronchiectasis and NTM Program, and is Co-Director of the NYU Pulmonary Faculty Practice. She is now serving in her 20th year as the Program Director of NYU's Pulmonary and Critical Care Medicine Fellowship. Dr. Addrizzo-Harris received her medical degree and completed her residency and fellowship training at New York University School of Medicine. Since completing her training, she was recruited to stay as a faculty member at NYU, where she has been a critical presence over the past 25 years. She has been instrumental in educating the next generation of pulmonary/critical care physicians and has won a number of awards for her teaching skills, most recently, the 2021 Outstanding Educator Award from the APCCMPD. Dr. Addrizzo-Harris has served on the board of the Association of Pulmonary and Critical Care Medicine Program Directors (APCCMPD), including serving as President from 2006-2007. Academically, she authored 44 peer-reviewed publications and 57 scientific abstracts presented at international conferences. She has participated in numerous clinical trials, many as PI. Dr. Addrizzo-Harris has been recognized as a Distinguished CHEST Educator each year since its inception in 2017 and received the Distinguished Service Award in 2019.
During her leadership tenure with CHEST, Dr. Addrizzo-Harris has served on the Marketing Committee, the Health and Science Policy Committee (Chair from 2007-2009), Government Relations Committee, Scientific Program Committee, Education Committee, Governance Committee, Editorial Board for CHEST Physician, Professional Standards Committee (Chair 2016-2018), Board of Regents, and CHEST Foundation Board of Trustees. Most recently, Dr. Addrizzo-Harris served as the President of the CHEST Foundation from 2018-2019 and Co-Chair of the Foundation Awards Committee from 2015-2020. She will serve as the sixth woman to lead the American College of Chest Physicians.
Doreen J. Addrizzo-Harris, MD, FCCP, is a pulmonary/critical care physician with an extensive background in bronchiectasis and non-tuberculous mycobacterial infection and medical education.
Dr. Addrizzo-Harris is currently a Professor of Medicine at the NYU Grossman School of Medicine. She serves as the Associate Division Director for Clinical and Faculty Affairs, is the Director of the NYU Bronchiectasis and NTM Program, and is Co-Director of the NYU Pulmonary Faculty Practice. She is now serving in her 20th year as the Program Director of NYU's Pulmonary and Critical Care Medicine Fellowship. Dr. Addrizzo-Harris received her medical degree and completed her residency and fellowship training at New York University School of Medicine. Since completing her training, she was recruited to stay as a faculty member at NYU, where she has been a critical presence over the past 25 years. She has been instrumental in educating the next generation of pulmonary/critical care physicians and has won a number of awards for her teaching skills, most recently, the 2021 Outstanding Educator Award from the APCCMPD. Dr. Addrizzo-Harris has served on the board of the Association of Pulmonary and Critical Care Medicine Program Directors (APCCMPD), including serving as President from 2006-2007. Academically, she authored 44 peer-reviewed publications and 57 scientific abstracts presented at international conferences. She has participated in numerous clinical trials, many as PI. Dr. Addrizzo-Harris has been recognized as a Distinguished CHEST Educator each year since its inception in 2017 and received the Distinguished Service Award in 2019.
During her leadership tenure with CHEST, Dr. Addrizzo-Harris has served on the Marketing Committee, the Health and Science Policy Committee (Chair from 2007-2009), Government Relations Committee, Scientific Program Committee, Education Committee, Governance Committee, Editorial Board for CHEST Physician, Professional Standards Committee (Chair 2016-2018), Board of Regents, and CHEST Foundation Board of Trustees. Most recently, Dr. Addrizzo-Harris served as the President of the CHEST Foundation from 2018-2019 and Co-Chair of the Foundation Awards Committee from 2015-2020. She will serve as the sixth woman to lead the American College of Chest Physicians.
Doreen J. Addrizzo-Harris, MD, FCCP, is a pulmonary/critical care physician with an extensive background in bronchiectasis and non-tuberculous mycobacterial infection and medical education.
Dr. Addrizzo-Harris is currently a Professor of Medicine at the NYU Grossman School of Medicine. She serves as the Associate Division Director for Clinical and Faculty Affairs, is the Director of the NYU Bronchiectasis and NTM Program, and is Co-Director of the NYU Pulmonary Faculty Practice. She is now serving in her 20th year as the Program Director of NYU's Pulmonary and Critical Care Medicine Fellowship. Dr. Addrizzo-Harris received her medical degree and completed her residency and fellowship training at New York University School of Medicine. Since completing her training, she was recruited to stay as a faculty member at NYU, where she has been a critical presence over the past 25 years. She has been instrumental in educating the next generation of pulmonary/critical care physicians and has won a number of awards for her teaching skills, most recently, the 2021 Outstanding Educator Award from the APCCMPD. Dr. Addrizzo-Harris has served on the board of the Association of Pulmonary and Critical Care Medicine Program Directors (APCCMPD), including serving as President from 2006-2007. Academically, she authored 44 peer-reviewed publications and 57 scientific abstracts presented at international conferences. She has participated in numerous clinical trials, many as PI. Dr. Addrizzo-Harris has been recognized as a Distinguished CHEST Educator each year since its inception in 2017 and received the Distinguished Service Award in 2019.
During her leadership tenure with CHEST, Dr. Addrizzo-Harris has served on the Marketing Committee, the Health and Science Policy Committee (Chair from 2007-2009), Government Relations Committee, Scientific Program Committee, Education Committee, Governance Committee, Editorial Board for CHEST Physician, Professional Standards Committee (Chair 2016-2018), Board of Regents, and CHEST Foundation Board of Trustees. Most recently, Dr. Addrizzo-Harris served as the President of the CHEST Foundation from 2018-2019 and Co-Chair of the Foundation Awards Committee from 2015-2020. She will serve as the sixth woman to lead the American College of Chest Physicians.
Home O2 in COPD. Eradicating COVID-19. mRNA and beyond. COVID-19 treatment, so far. Awake proning in COVID-19. Home ventilation. Interprofessional team approach to palliative extubation.
Airways disorders
Updated guidelines on the use of home O2 in COPD: A much-needed respite
The use of long-term oxygen therapy (LTOT, oxygen prescribed for at least 15 h/day) in patients with COPD and chronic hypoxemia has been standard of care based on trials from the 1980s that conferred a survival benefit with the use of continuous oxygen (Ann Internal Med. 1980;93[3]:391-8). More recently, LTOT has not shown to improve survival or delay time to the hospitalization in patients with stable COPD and resting or exercise-induced moderate desaturation (N Engl J Med. 2016;375[17]:1617-27). Thus far, existing recommendations had been semi-inclusive in patient selection. A fundamental lack of evidence-based clinical practice guidelines prompted additional research into patient selection, portable oxygen technology, advocacy for improved oxygen therapy financing, and updating of policies (Jacobs et al., Ann Am Thorac Soc. 2018;15[12]:1369-81). With over a million patients in the United States being prescribed home oxygen and reported disconnect in-home oxygen needs/experiences across disease processes, lifestyles, and oxygen supply requirements, the 2020 American Thoracic Society (ATS) workshop on optimizing home oxygen therapy sought to answer critical questions in the use of LTOT for COPD patients (AlMutairi, et al. Respir Care. 2018;63[11]:1321-30; Jacobs, et al. Am J Respir Crit Care Med. 2020;202[10]:e121-e141).
Kadambari Vijaykumar, MD
Fellow-in-Training Member
Dharani Kumari Narendra, MBBS, FCCP
Steering Committee Member
Chest infections
Eradicating COVID-19 scourge: It is up to all of us— get vaccinated!
2021 brings hope, spurred by the availability of several effective COVID-19 vaccines – unprecedented scientific advances, considering that these vaccines were developed in record time. We have stark choices: while some individuals ignore scientific evidence and refuse to take the vaccine, we from the Chest Infections NetWork urge an alternative and imperative choice. As health providers caring for COVID-19 patients, we first-hand witness the horrors of dying alone in a hospital bed – far away from beloved ones. I have a sticker on my car that says: If you do not like your mask, you will not like my ventilator. With the advent of vaccines, I plan on replacing this sticker: If you do not want to get vaccinated, you will not like my ventilator. When the vaccine became available at my institution, I was the first to roll up my sleeve and feel the pinch in my upper arm. I urge you all to do the same. Make a difference, do your part – get vaccinated.
Marcos I. Restrepo, MD, MSc, PhD
Chair
Clinical pulmonary medicine
COVID-19 vaccines – mRNA and beyond
We currently have two COVID-19 mRNA vaccines with US FDA emergency use authorization (EUA) for use in individuals less than or equal to age 18 years – Pfizer and Moderna. They work by introducing mRNA into a muscle cell that instructs the host cell ribosomes to express Sars-CoV-2 spike proteins, thereby triggering a systemic immune response.
Both are two-dose regimens, with Pfizer’s 21 days apart and requires storage at -75 C, and Moderna’s 28 days apart, requiring storage at -20 C.
Presently in development are three more vaccines. AstraZeneca (AZ) and Johnson & Johnson (JnJ) use an adenovirus vector. Both vaccines are stable at standard refrigerator temperatures. AZ’s results were mixed – with two, full-size doses efficacy at 62% effective, but with a half-dose followed by a full dose, efficacy was 90%. Novavax candidate works differently - it’s a protein subunit vaccine and uses a lab-made version of the SARS-CoV-2 spike protein, mixed with an adjuvant to help trigger the immune system. Results from all trials are eagerly awaited.
Mary Jo S. Farmer, MD, PhD, FCCP
Steering Committee Member
Shyam Subramanian, MD, FCCP
Chair
Clinical research and quality improvement
COVID-19 treatment, so far!
COVID-19 has turned rapidly into a fatal illness, causing over 1.8 million deaths worldwide so far. The pandemic has also showed us the power of adaptive trials, multi-arm trials, and the role for collaboration across the global scientific community. A few significant studies are worth mentioning.
Possible future therapies include antiviral monoclonal antibodies, bamlanivimab (Chen P, et al. N Engl J Med. 2020; online ahead of print); early convalescent plasma (Libster R, et al. N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMoa2033700); and casirivimab-imdevimab (Baum A, et al. Science. 2020 Nov 27 doi: 10.1126/science.abe2402). Development of mRNA COVID-19 vaccines can help with primary prevention and herd immunity (Polack FP, et al. N Engl J Med. 2020;383[27]:2603; Baden LR, et al. N Engl J Med. 2020; Dec 30; doi: 10.1056/NEJMoa2035389).
We are starting to understand why COVID-19 infection is more pathogenic in some, how to predict development of severe disease, and how to best treat respiratory failure. Defeating the pandemic will require ongoing international collaboration in research, development, and resource allocation.
Muhammad Hayat Syed, MBBS
Ankita Agarwal, MD
Fellows-in-Training Members
Critical care
Awake proning in COVID-19
Prone positioning has been shown to improve pulmonary mechanics in intubated patients with acute respiratory distress syndrome (ARDS). Proposed mechanisms for these benefits include shape matching, reversing the pleural pressure gradient, homogenizing distribution of pleural pressures, reducing the impact of the heart and abdomen on the lungs, and maintaining distribution of perfusion. Application of prone positioning has also been shown to reduce mortality in severe ARDS (Guérin, et al. N Engl J Med. 2013;368(23):2159-68). With the COVID-19 pandemic, clinicians have extrapolated that nonintubated patients with severe hypoxia may benefit from awake proning in the hopes of improving oxygenation and decreasing need for intubation. But, what’s the evidence so far?
Kathryn Pendleton, MD
Viren Kaul, MD
Steering Committee Members
Home-Based Mechanical Ventilation and Neuromuscular Disease
New horizons in home ventilation
Phasing out a particular ventilator (Philips Respironics Trilogy 100 ventilator) has everyone on a steep learning curve with the replacement (Trilogy EVO). Most features are replicated in the EVO, including volume/pressure control and pressure-supported modes, mouthpiece ventilation, active/passive circuit capability, and portability (11.5 lb). Upgrades include longer battery life (15 hours; 7.5 hours internal/7.5 hours detachable) and use in pediatric patients now greater than or equal to 2.5 kg.
Other significant improvements include lower flow trigger sensitivity to accommodate patients with severe respiratory muscle weakness, a fast start AVAPS with rapid breath-to-breath 3 cm H20 increases for the first minute to rapidly reach target tidal volume, and breath-to-breath auto-EPAP sensing of upper airway resistance to maintain airway patency for patients with upper airway obstruction.
Internal bluetooth transmission to cloud-based monitoring (Care OrchestratorTM) expands access to patients without wi-fi or cellular service. New monitoring modules, SpO2 and EtCO2, and transcutaneous CO2 monitoring (Sentec), transmit to cloud-based monitoring (EVO EtCs2 spring 2021).
These welcome improvements allow clinicians to better match ventilator settings to the patients’ evolving physiology and provide flexibility and connectivity to optimize long-term care.
Karin Provost, DO, PhD
Steering Committee Member
Janet Hilbert, MD
NetWork Member
Online resources
EVO e-learning curriculum
Interprofessional team
Interprofessional team approach to palliative extubation
The emotional burden of caring for patients at the end of life affects all members of the care team. Palliative (or compassionate) extubation consists of the withdrawal of mechanical ventilation when the absolute priority in care delivery is to afford comfort and allow for natural death to occur. Rapid withdrawal of ventilatory support may lead to significant respiratory distress, and the critical care team has an obligation to ensure patient comfort during the dying process (Truog RD, et al. Crit Care Med. 2008;36[3]:953). Registered nurses (RN) are primarily responsible for the titration of sedation/analgesia and should be included in discussions regarding medication selection. It is imperative that neuromuscular blockade is absent, and benzodiazepines and/or opioids should be initiated prior to palliative extubation (Lanken PN, et al. Am J Respir Crit Care Med. 2008;177:912). Respiratory therapists (RT) are responsible for endotracheal tube removal despite rare participation in end-of-life discussions (Grandhige AP, et al. Respir Care. 2016;61[7]:891). It is recommended that an experienced physician, RN, and RT be readily available to respond quickly to any signs of distress (Downar J, et al. Intensive Care Med. 2016;42:1003). Regular debriefing sessions exploring team actions and communication dynamics are advised following end-of-life care (Ho A, et al. J Interprof Care. 2016;30[6]:795-803). Palliative extubation demands meticulous planning and clear communication among all team members (physician, RN, RT) and the patient’s family. Poor planning may result in physical and emotional suffering for the patient and difficult bereavement for the family (Coradazi A, et al. Hos Pal Med Int J. 2019;3[1]:10-14). Interprofessional team-based care results from intentional teams that exhibit collective identity and shared responsibility for the patients they serve (Core Competencies for Interprofessional Education Collaborative Practice, 2016). An inclusive and interprofessional approach to withdrawal of mechanical ventilation is key to both quality patient care and provider wellbeing.
Rebecca Anna Gersten, MD
Steering Committee Member
Samantha Davis, MS, RRT
Steering Committee Member
Munish Luthra, MD, FCCP
Vice-Chair Committee
Airways disorders
Updated guidelines on the use of home O2 in COPD: A much-needed respite
The use of long-term oxygen therapy (LTOT, oxygen prescribed for at least 15 h/day) in patients with COPD and chronic hypoxemia has been standard of care based on trials from the 1980s that conferred a survival benefit with the use of continuous oxygen (Ann Internal Med. 1980;93[3]:391-8). More recently, LTOT has not shown to improve survival or delay time to the hospitalization in patients with stable COPD and resting or exercise-induced moderate desaturation (N Engl J Med. 2016;375[17]:1617-27). Thus far, existing recommendations had been semi-inclusive in patient selection. A fundamental lack of evidence-based clinical practice guidelines prompted additional research into patient selection, portable oxygen technology, advocacy for improved oxygen therapy financing, and updating of policies (Jacobs et al., Ann Am Thorac Soc. 2018;15[12]:1369-81). With over a million patients in the United States being prescribed home oxygen and reported disconnect in-home oxygen needs/experiences across disease processes, lifestyles, and oxygen supply requirements, the 2020 American Thoracic Society (ATS) workshop on optimizing home oxygen therapy sought to answer critical questions in the use of LTOT for COPD patients (AlMutairi, et al. Respir Care. 2018;63[11]:1321-30; Jacobs, et al. Am J Respir Crit Care Med. 2020;202[10]:e121-e141).
Kadambari Vijaykumar, MD
Fellow-in-Training Member
Dharani Kumari Narendra, MBBS, FCCP
Steering Committee Member
Chest infections
Eradicating COVID-19 scourge: It is up to all of us— get vaccinated!
2021 brings hope, spurred by the availability of several effective COVID-19 vaccines – unprecedented scientific advances, considering that these vaccines were developed in record time. We have stark choices: while some individuals ignore scientific evidence and refuse to take the vaccine, we from the Chest Infections NetWork urge an alternative and imperative choice. As health providers caring for COVID-19 patients, we first-hand witness the horrors of dying alone in a hospital bed – far away from beloved ones. I have a sticker on my car that says: If you do not like your mask, you will not like my ventilator. With the advent of vaccines, I plan on replacing this sticker: If you do not want to get vaccinated, you will not like my ventilator. When the vaccine became available at my institution, I was the first to roll up my sleeve and feel the pinch in my upper arm. I urge you all to do the same. Make a difference, do your part – get vaccinated.
Marcos I. Restrepo, MD, MSc, PhD
Chair
Clinical pulmonary medicine
COVID-19 vaccines – mRNA and beyond
We currently have two COVID-19 mRNA vaccines with US FDA emergency use authorization (EUA) for use in individuals less than or equal to age 18 years – Pfizer and Moderna. They work by introducing mRNA into a muscle cell that instructs the host cell ribosomes to express Sars-CoV-2 spike proteins, thereby triggering a systemic immune response.
Both are two-dose regimens, with Pfizer’s 21 days apart and requires storage at -75 C, and Moderna’s 28 days apart, requiring storage at -20 C.
Presently in development are three more vaccines. AstraZeneca (AZ) and Johnson & Johnson (JnJ) use an adenovirus vector. Both vaccines are stable at standard refrigerator temperatures. AZ’s results were mixed – with two, full-size doses efficacy at 62% effective, but with a half-dose followed by a full dose, efficacy was 90%. Novavax candidate works differently - it’s a protein subunit vaccine and uses a lab-made version of the SARS-CoV-2 spike protein, mixed with an adjuvant to help trigger the immune system. Results from all trials are eagerly awaited.
Mary Jo S. Farmer, MD, PhD, FCCP
Steering Committee Member
Shyam Subramanian, MD, FCCP
Chair
Clinical research and quality improvement
COVID-19 treatment, so far!
COVID-19 has turned rapidly into a fatal illness, causing over 1.8 million deaths worldwide so far. The pandemic has also showed us the power of adaptive trials, multi-arm trials, and the role for collaboration across the global scientific community. A few significant studies are worth mentioning.
Possible future therapies include antiviral monoclonal antibodies, bamlanivimab (Chen P, et al. N Engl J Med. 2020; online ahead of print); early convalescent plasma (Libster R, et al. N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMoa2033700); and casirivimab-imdevimab (Baum A, et al. Science. 2020 Nov 27 doi: 10.1126/science.abe2402). Development of mRNA COVID-19 vaccines can help with primary prevention and herd immunity (Polack FP, et al. N Engl J Med. 2020;383[27]:2603; Baden LR, et al. N Engl J Med. 2020; Dec 30; doi: 10.1056/NEJMoa2035389).
We are starting to understand why COVID-19 infection is more pathogenic in some, how to predict development of severe disease, and how to best treat respiratory failure. Defeating the pandemic will require ongoing international collaboration in research, development, and resource allocation.
Muhammad Hayat Syed, MBBS
Ankita Agarwal, MD
Fellows-in-Training Members
Critical care
Awake proning in COVID-19
Prone positioning has been shown to improve pulmonary mechanics in intubated patients with acute respiratory distress syndrome (ARDS). Proposed mechanisms for these benefits include shape matching, reversing the pleural pressure gradient, homogenizing distribution of pleural pressures, reducing the impact of the heart and abdomen on the lungs, and maintaining distribution of perfusion. Application of prone positioning has also been shown to reduce mortality in severe ARDS (Guérin, et al. N Engl J Med. 2013;368(23):2159-68). With the COVID-19 pandemic, clinicians have extrapolated that nonintubated patients with severe hypoxia may benefit from awake proning in the hopes of improving oxygenation and decreasing need for intubation. But, what’s the evidence so far?
Kathryn Pendleton, MD
Viren Kaul, MD
Steering Committee Members
Home-Based Mechanical Ventilation and Neuromuscular Disease
New horizons in home ventilation
Phasing out a particular ventilator (Philips Respironics Trilogy 100 ventilator) has everyone on a steep learning curve with the replacement (Trilogy EVO). Most features are replicated in the EVO, including volume/pressure control and pressure-supported modes, mouthpiece ventilation, active/passive circuit capability, and portability (11.5 lb). Upgrades include longer battery life (15 hours; 7.5 hours internal/7.5 hours detachable) and use in pediatric patients now greater than or equal to 2.5 kg.
Other significant improvements include lower flow trigger sensitivity to accommodate patients with severe respiratory muscle weakness, a fast start AVAPS with rapid breath-to-breath 3 cm H20 increases for the first minute to rapidly reach target tidal volume, and breath-to-breath auto-EPAP sensing of upper airway resistance to maintain airway patency for patients with upper airway obstruction.
Internal bluetooth transmission to cloud-based monitoring (Care OrchestratorTM) expands access to patients without wi-fi or cellular service. New monitoring modules, SpO2 and EtCO2, and transcutaneous CO2 monitoring (Sentec), transmit to cloud-based monitoring (EVO EtCs2 spring 2021).
These welcome improvements allow clinicians to better match ventilator settings to the patients’ evolving physiology and provide flexibility and connectivity to optimize long-term care.
Karin Provost, DO, PhD
Steering Committee Member
Janet Hilbert, MD
NetWork Member
Online resources
EVO e-learning curriculum
Interprofessional team
Interprofessional team approach to palliative extubation
The emotional burden of caring for patients at the end of life affects all members of the care team. Palliative (or compassionate) extubation consists of the withdrawal of mechanical ventilation when the absolute priority in care delivery is to afford comfort and allow for natural death to occur. Rapid withdrawal of ventilatory support may lead to significant respiratory distress, and the critical care team has an obligation to ensure patient comfort during the dying process (Truog RD, et al. Crit Care Med. 2008;36[3]:953). Registered nurses (RN) are primarily responsible for the titration of sedation/analgesia and should be included in discussions regarding medication selection. It is imperative that neuromuscular blockade is absent, and benzodiazepines and/or opioids should be initiated prior to palliative extubation (Lanken PN, et al. Am J Respir Crit Care Med. 2008;177:912). Respiratory therapists (RT) are responsible for endotracheal tube removal despite rare participation in end-of-life discussions (Grandhige AP, et al. Respir Care. 2016;61[7]:891). It is recommended that an experienced physician, RN, and RT be readily available to respond quickly to any signs of distress (Downar J, et al. Intensive Care Med. 2016;42:1003). Regular debriefing sessions exploring team actions and communication dynamics are advised following end-of-life care (Ho A, et al. J Interprof Care. 2016;30[6]:795-803). Palliative extubation demands meticulous planning and clear communication among all team members (physician, RN, RT) and the patient’s family. Poor planning may result in physical and emotional suffering for the patient and difficult bereavement for the family (Coradazi A, et al. Hos Pal Med Int J. 2019;3[1]:10-14). Interprofessional team-based care results from intentional teams that exhibit collective identity and shared responsibility for the patients they serve (Core Competencies for Interprofessional Education Collaborative Practice, 2016). An inclusive and interprofessional approach to withdrawal of mechanical ventilation is key to both quality patient care and provider wellbeing.
Rebecca Anna Gersten, MD
Steering Committee Member
Samantha Davis, MS, RRT
Steering Committee Member
Munish Luthra, MD, FCCP
Vice-Chair Committee
Airways disorders
Updated guidelines on the use of home O2 in COPD: A much-needed respite
The use of long-term oxygen therapy (LTOT, oxygen prescribed for at least 15 h/day) in patients with COPD and chronic hypoxemia has been standard of care based on trials from the 1980s that conferred a survival benefit with the use of continuous oxygen (Ann Internal Med. 1980;93[3]:391-8). More recently, LTOT has not shown to improve survival or delay time to the hospitalization in patients with stable COPD and resting or exercise-induced moderate desaturation (N Engl J Med. 2016;375[17]:1617-27). Thus far, existing recommendations had been semi-inclusive in patient selection. A fundamental lack of evidence-based clinical practice guidelines prompted additional research into patient selection, portable oxygen technology, advocacy for improved oxygen therapy financing, and updating of policies (Jacobs et al., Ann Am Thorac Soc. 2018;15[12]:1369-81). With over a million patients in the United States being prescribed home oxygen and reported disconnect in-home oxygen needs/experiences across disease processes, lifestyles, and oxygen supply requirements, the 2020 American Thoracic Society (ATS) workshop on optimizing home oxygen therapy sought to answer critical questions in the use of LTOT for COPD patients (AlMutairi, et al. Respir Care. 2018;63[11]:1321-30; Jacobs, et al. Am J Respir Crit Care Med. 2020;202[10]:e121-e141).
Kadambari Vijaykumar, MD
Fellow-in-Training Member
Dharani Kumari Narendra, MBBS, FCCP
Steering Committee Member
Chest infections
Eradicating COVID-19 scourge: It is up to all of us— get vaccinated!
2021 brings hope, spurred by the availability of several effective COVID-19 vaccines – unprecedented scientific advances, considering that these vaccines were developed in record time. We have stark choices: while some individuals ignore scientific evidence and refuse to take the vaccine, we from the Chest Infections NetWork urge an alternative and imperative choice. As health providers caring for COVID-19 patients, we first-hand witness the horrors of dying alone in a hospital bed – far away from beloved ones. I have a sticker on my car that says: If you do not like your mask, you will not like my ventilator. With the advent of vaccines, I plan on replacing this sticker: If you do not want to get vaccinated, you will not like my ventilator. When the vaccine became available at my institution, I was the first to roll up my sleeve and feel the pinch in my upper arm. I urge you all to do the same. Make a difference, do your part – get vaccinated.
Marcos I. Restrepo, MD, MSc, PhD
Chair
Clinical pulmonary medicine
COVID-19 vaccines – mRNA and beyond
We currently have two COVID-19 mRNA vaccines with US FDA emergency use authorization (EUA) for use in individuals less than or equal to age 18 years – Pfizer and Moderna. They work by introducing mRNA into a muscle cell that instructs the host cell ribosomes to express Sars-CoV-2 spike proteins, thereby triggering a systemic immune response.
Both are two-dose regimens, with Pfizer’s 21 days apart and requires storage at -75 C, and Moderna’s 28 days apart, requiring storage at -20 C.
Presently in development are three more vaccines. AstraZeneca (AZ) and Johnson & Johnson (JnJ) use an adenovirus vector. Both vaccines are stable at standard refrigerator temperatures. AZ’s results were mixed – with two, full-size doses efficacy at 62% effective, but with a half-dose followed by a full dose, efficacy was 90%. Novavax candidate works differently - it’s a protein subunit vaccine and uses a lab-made version of the SARS-CoV-2 spike protein, mixed with an adjuvant to help trigger the immune system. Results from all trials are eagerly awaited.
Mary Jo S. Farmer, MD, PhD, FCCP
Steering Committee Member
Shyam Subramanian, MD, FCCP
Chair
Clinical research and quality improvement
COVID-19 treatment, so far!
COVID-19 has turned rapidly into a fatal illness, causing over 1.8 million deaths worldwide so far. The pandemic has also showed us the power of adaptive trials, multi-arm trials, and the role for collaboration across the global scientific community. A few significant studies are worth mentioning.
Possible future therapies include antiviral monoclonal antibodies, bamlanivimab (Chen P, et al. N Engl J Med. 2020; online ahead of print); early convalescent plasma (Libster R, et al. N Engl J Med. 2021 Jan 6. doi: 10.1056/NEJMoa2033700); and casirivimab-imdevimab (Baum A, et al. Science. 2020 Nov 27 doi: 10.1126/science.abe2402). Development of mRNA COVID-19 vaccines can help with primary prevention and herd immunity (Polack FP, et al. N Engl J Med. 2020;383[27]:2603; Baden LR, et al. N Engl J Med. 2020; Dec 30; doi: 10.1056/NEJMoa2035389).
We are starting to understand why COVID-19 infection is more pathogenic in some, how to predict development of severe disease, and how to best treat respiratory failure. Defeating the pandemic will require ongoing international collaboration in research, development, and resource allocation.
Muhammad Hayat Syed, MBBS
Ankita Agarwal, MD
Fellows-in-Training Members
Critical care
Awake proning in COVID-19
Prone positioning has been shown to improve pulmonary mechanics in intubated patients with acute respiratory distress syndrome (ARDS). Proposed mechanisms for these benefits include shape matching, reversing the pleural pressure gradient, homogenizing distribution of pleural pressures, reducing the impact of the heart and abdomen on the lungs, and maintaining distribution of perfusion. Application of prone positioning has also been shown to reduce mortality in severe ARDS (Guérin, et al. N Engl J Med. 2013;368(23):2159-68). With the COVID-19 pandemic, clinicians have extrapolated that nonintubated patients with severe hypoxia may benefit from awake proning in the hopes of improving oxygenation and decreasing need for intubation. But, what’s the evidence so far?
Kathryn Pendleton, MD
Viren Kaul, MD
Steering Committee Members
Home-Based Mechanical Ventilation and Neuromuscular Disease
New horizons in home ventilation
Phasing out a particular ventilator (Philips Respironics Trilogy 100 ventilator) has everyone on a steep learning curve with the replacement (Trilogy EVO). Most features are replicated in the EVO, including volume/pressure control and pressure-supported modes, mouthpiece ventilation, active/passive circuit capability, and portability (11.5 lb). Upgrades include longer battery life (15 hours; 7.5 hours internal/7.5 hours detachable) and use in pediatric patients now greater than or equal to 2.5 kg.
Other significant improvements include lower flow trigger sensitivity to accommodate patients with severe respiratory muscle weakness, a fast start AVAPS with rapid breath-to-breath 3 cm H20 increases for the first minute to rapidly reach target tidal volume, and breath-to-breath auto-EPAP sensing of upper airway resistance to maintain airway patency for patients with upper airway obstruction.
Internal bluetooth transmission to cloud-based monitoring (Care OrchestratorTM) expands access to patients without wi-fi or cellular service. New monitoring modules, SpO2 and EtCO2, and transcutaneous CO2 monitoring (Sentec), transmit to cloud-based monitoring (EVO EtCs2 spring 2021).
These welcome improvements allow clinicians to better match ventilator settings to the patients’ evolving physiology and provide flexibility and connectivity to optimize long-term care.
Karin Provost, DO, PhD
Steering Committee Member
Janet Hilbert, MD
NetWork Member
Online resources
EVO e-learning curriculum
Interprofessional team
Interprofessional team approach to palliative extubation
The emotional burden of caring for patients at the end of life affects all members of the care team. Palliative (or compassionate) extubation consists of the withdrawal of mechanical ventilation when the absolute priority in care delivery is to afford comfort and allow for natural death to occur. Rapid withdrawal of ventilatory support may lead to significant respiratory distress, and the critical care team has an obligation to ensure patient comfort during the dying process (Truog RD, et al. Crit Care Med. 2008;36[3]:953). Registered nurses (RN) are primarily responsible for the titration of sedation/analgesia and should be included in discussions regarding medication selection. It is imperative that neuromuscular blockade is absent, and benzodiazepines and/or opioids should be initiated prior to palliative extubation (Lanken PN, et al. Am J Respir Crit Care Med. 2008;177:912). Respiratory therapists (RT) are responsible for endotracheal tube removal despite rare participation in end-of-life discussions (Grandhige AP, et al. Respir Care. 2016;61[7]:891). It is recommended that an experienced physician, RN, and RT be readily available to respond quickly to any signs of distress (Downar J, et al. Intensive Care Med. 2016;42:1003). Regular debriefing sessions exploring team actions and communication dynamics are advised following end-of-life care (Ho A, et al. J Interprof Care. 2016;30[6]:795-803). Palliative extubation demands meticulous planning and clear communication among all team members (physician, RN, RT) and the patient’s family. Poor planning may result in physical and emotional suffering for the patient and difficult bereavement for the family (Coradazi A, et al. Hos Pal Med Int J. 2019;3[1]:10-14). Interprofessional team-based care results from intentional teams that exhibit collective identity and shared responsibility for the patients they serve (Core Competencies for Interprofessional Education Collaborative Practice, 2016). An inclusive and interprofessional approach to withdrawal of mechanical ventilation is key to both quality patient care and provider wellbeing.
Rebecca Anna Gersten, MD
Steering Committee Member
Samantha Davis, MS, RRT
Steering Committee Member
Munish Luthra, MD, FCCP
Vice-Chair Committee
In case you missed it ...CHEST Annual Meeting 2020 Award Recipients
ANNUAL AWARDS
Master FCCP
Nancy A. Collop MD, Master FCCP
College Medalist Award
Neil R. MacIntyre, MD, FCCP
Distinguished Service Award
Lisa K. Moores, MD, FCCP
Master Clinician Educator
William F. Kelly, MD, FCCP
David A. Schulman, MD, MPH, FCCP
Early Career Clinician Educator
Subani Chandra, MD, FCCP
Alfred Soffer Award for Editorial Excellence
Barbara Anderson, CHEST Staff
Laura Lipsey, CHEST Staff
Presidential Citation
Mangala Narasimhan, DO, FCCP
Renli Qiao, MD, PhD, FCCP
HONOR LECTURE AND MEMORIAL AWARDS
Edward C. Rosenow III, MD, Master FCCP/Master Teacher Endowed Honor Lecture Evolving Therapies in ANCA-Associated Vasculitides
Joseph P. Lynch, III, MD, FCCP
The lecture is generously funded by the CHEST Foundation.Distinguished Scientist Honor Lecture in Cardiopulmonary PhysiologyHelping the Dyspneic Patient: Clinical Physiology Matters!
Denis E. O’Donnell, MD, MBBCh, FCCP
The lecture is generously funded by the CHEST Foundation.Presidential Honor LectureCOPD Management: We’ve Come So Far
Darcy D. Marciniuk, MD, Master FCCP
Thomas L. Petty, MD, Master FCCP Memorial LectureReal World Research - What Would Dr. Petty Say?
Mary Hart, RRT, MS, FCCP
The lecture is generously funded by the CHEST Foundation.Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical VentilationNavigating to Home NIV Nirvana: What Would Margaret Do?
Peter C. Gay, MD, MS, FCCP
The Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical Ventilation is generously supported by International Ventilator Users Network of Post-Polio Health International and the CHEST Foundation.Pasquale Ciaglia Memorial Lecture in Interventional MedicineRaising the Bar: The Interventional Pulmonary Outcomes Group
Lonny B. Yarmus, DO, MBA, FCCP
The lecture is generously funded by the CHEST Foundation.
Roger C. Bone Memorial Lecture in Critical CareTo SIRS with Love: Dr. Roger Bone’s Continued Influence on Early Sepsis Care
Emanuel P. Rivers, MD, MPH, FCCP
The lecture is generously funded by the CHEST Foundation.Murray Kornfeld Memorial Founders LectureOur Pneumonia Journey: The Lungs and Beyond
Marcos I. Restrepo, MD, PhD, FCCP
The lecture is generously funded by the CHEST Foundation.
CHEST FOUNDATION GRANT AWARDS
The GlaxoSmithKline Distinguished Scholar in Respiratory Health
Deepa Gotur, MD, FCCP
Cytokine Release in SARS COV2 Viral Illness and Trends of Inflammasome Expression in Acute Respiratory Distress Syndrome Manifestations and ManagementThis grant is supported by an endowed fund from GlaxoSmithKline.CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency
Paul R. Ellis, MBChB
Cardiovascular Outcomes and Phenotypes in Pulmonary Exacerbations of Alpha-1 AntitrypsinThis grant is jointly supported by the CHEST Foundation and the Alpha-1 Foundation.CHEST Foundation Research Grant in Women’s Lung Health
Shannon E. Kay, MD
Sex-specific Gene Expression in AsthmaThis grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease
Davide Biondini, MD, PhD
Role of the Immune Check Points (CTLA-4 and PD-1) in the Development or Evasion of Smoking-Induced Chronic Obstructive Pulmonary Disease
Andrew J. Gangemi, MD
Are Sleep Health, Nicotine Metabolism, and Airway Inflammation Mechanisms for Differences in Lung Function between African American and Non-Hispanic White Smokers? A Proof-of-Concept ExaminationThese grants are supported by AstraZeneca LP.CHEST Foundation Research Grant in Critical Care
Mounica Vallurupalli, MD
Evaluating the Impact of Clonal Hematopoiesis on Host Immune Response During Sepsis
This grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Lung Cancer
Stefanie Mason, MD
Implications of Longitudinal Muscle-Mass Trajectories in Lung CancerThis grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Venous Thromboembolism
Jansen N. Seheult, MD, MBBCh
Untangling the NET: Neutrophil Activation as the Driver of Venous Thromboembolism in Coronavirus Disease 2019This grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases
Bryan A. Garcia, MD
Longitudinal Proteomic Endotyping of Patients with Nontuberculous Mycobacterial Lung InfectionsThis grant is supported by Insmed Incorporated.CHEST Foundation Research Grant in Cystic Fibrosis
Jeffrey Barry, MD
Eosinophilia as a Biomarker for Worse Outcomes in Cystic Fibrosis
Kristina Montemayor, MD
The Association of Sex Hormones and Respiratory Morbidity in Individuals with Cystic FibrosisThese grants are supported by Vertex Pharmaceuticals.John R. Addrizzo, MD, FCCP Research Grant in Sarcoidosis
Changwan Ryu, MD
Extracellular Matrix Proteins as a Biomarker for Stage IV SarcoidosisThis grant is in honor of John R. Addrizzo, MD, FCCP and is jointly supported by the Addrizzo family and the CHEST Foundation.CHEST Foundation Research Grant in Severe Asthma
Isaretta L. Riley, MD, MPH
Coping with Asthma through Life Management (CALM)This grant is funded by AstraZeneca LP.CHEST Foundation Research Grant in Pulmonary Fibrosis
Sarah Beshay, MD
COPA Syndrome-Associated Mutations in Lung Transplant Recipients for Pulmonary Fibrosis
Erica D. Farrand, MD
The Future of Telehealth in Interstitial Lung DiseaseThese grants are supported by Boehringer Ingelheim Pharmaceuticals and Genentech, Inc.CHEST Foundation Research Grant in Sleep Medicine
Tetyana Kendzerska, MD, PhD
The Role of Sleep and Circadian Disturbances in Cancer Development and Progression: A Historical Multicenter Clinical Cohort Study
Nancy Stewart, DO
Improving COPD/OSA Overlap Syndrome Pre-Discharge Care DeliveryThese grants are funded by Jazz Pharmaceuticals, Inc.CHEST Foundation and Association of Critical Care Medicine Program Directors Award Research Grant in Medical Education
Ilana R. Krumm, MD
What’s good about Soul Food? Discovering and Analyzing Elements of an ICU Team Group Discussion Which Improve Provider WellnessThis grant is jointly supported by the CHEST Foundation and APCCMPD.CHEST Foundation and American Thoracic Society Research Grant in Diversity
Thomas S. Valley, MD, MSc
Understanding Differences in Delivery of Care Processes for Respiratory Failure by Race/EthnicityThis grant is jointly supported by the CHEST Foundation and ATS.CHEST Foundation Research Grant in COVID-19
David Furfaro, MD
Subphenotypes, Inflammatory Profiles, and Antibody Response in COVID-19 ARDSThis grant is supported by the CHEST Foundation.CHEST Foundation and American Thoracic Society Grant in COVID-19 and Diversity
Peter D. Jackson, MD
The Effect of the COVID-19 Pandemic on Tuberculosis Care in UgandaThis grant is jointly supported by the CHEST Foundation and ATS.CHEST Foundation Research Grant in Ultrasonography and COVID-19
Marjan M. Islam, MD
Thoracic Ultrasound in COVID-19: A Prospective Study Using Lung and Diaphragm Ultrasound in Evaluating Dyspnea in ICU Survivors with COVID-19 in a Post-ICU Clinic
Siddharth Dugar, MBBS
Spontaneous Echo Contrast in Lower Extremity and Correlation with Venous Velocity and Subsequent Deep Venous Thrombosis in Critically Ill COVID-19 PatientsThis grant is jointly supported by the CHEST Foundation and FUJIFILM SonoSite.
CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP
Ivan Nemorin, MBA, MS, RRT
Healthier Homes for Children-Community Asthma Prevention Program
Joseph Huang, MD
East Africa Training Initiative (EATI)
Aninda Das, MD, MBBS
Screening for Childhood Tuberculosis in Children 0-4 years of Age with Moderate to Severe Malnutrition in a Rural District of West Bengal, India
Trishual Siddharthan, MD
Establishing a Pulmonary and Critical Care Training Program in Uganda
Marina Lima, MD, MSc
Asmaland: The First Gamified Pediatric Asthma Educational Program in Portuguese
Roberta M. Kato, MD
Lung Power
These grants are supported by the CHEST Foundation.Alfred Soffer Research Award Winners
Mazen O. Al-Qadi, MD: RESPIRATORY VARIATION IN RIGHT ATRIAL PRESSURE PREDICTS RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH PRE-CAPILLARY PULMONARY HYPERTENSION
Valerie G. Press, MD: COST SAVING SIMULATION FOR THE TRANSITION FROM NEBULIZER TO COMBINATION OF NEBULIZER AND METERED-DOSE INHALERS (MD)
Young Investigator Award Winners
Gabriel E. Ortiz Jaimes, MD: CORRELATION OF CARDIAC OUTPUT MEASUREMENT BY GOAL-DIRECTED ECHOCARDIOGRAPHY PERFORMED BY INTENSIVISTS VS PULMONARY ARTERY CATHETER
Palakkumar Patel, MD: IMPACT OF HAVING PULMONARY HYPERTENSION IN PATIENTS ADMITTED WITH ACUTE EXACERBATION OF COPD IN THEIR HEALTHCARE UTILIZATION AND READMISSION: A US POPULATION COHORT STUDY
Top 5 Abstract Posters
Winner: Amr Alwakeel, MD: IMPACT OF A PLEURAL CARE PROGRAM ON THE PATHWAY TO DEFINITIVE PALLIATION OF MALIGNANT PLEURAL EFFUSIONS: A PRE-AND POST STUDY
Winner: Konstantinos Zorbas, MD: A SIMPLE PREDICTION SCORE FOR POSTOPERATIVE DEATH AFTER DECORTICATION
Winner: Yichen Wang, MD, MSc: CORONAVIRUS-RELATED HOSPITAL ADMISSIONS IN THE UNITED STATES IN 2016-2017
Runner up: Daniel Ospina-Delgado, MD: CHARACTERIZATION OF LARYNGEAL DISORDERS IN PATIENTS WITH EXCESSIVE CENTRAL AIRWAY COLLAPSE
Runner up: Vishal Vashistha, MD: TREATMENT PATTERNS AMONG LOWER-INCOME INDIAN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS OR ALK REARRANGEMENTS
Case Report Poster Winners
Faiza Khalid, MD: FORME FUSTE OF INTERMEDIATE SYNDROME (IMS) IN ORGANOPHOSPHATE POISOING (OPP): EXPERT OPINION GUIDELINE WITHOUT CLEAR END-POINT.
William Meng, MD: VINGT MILLE LIEUES SOUS LES MERS: A POISONOUS GUEST FROM THE BLUE SEA TOXIC INHALATION OF CORAL PALYTOXIN
Dhruv Amratia, MD: PULMONARY BLASTOMA: A RARE FORM OF LUNG CANCER
Melinda Becker, MD: ECMO-ASSISTED BRONCHOSCOPY FOR NEAR-COMPLETE TRACHEAL OBSTRUCTION
Brittany Blass, PA-C: A CASE OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS WITH UNDERLYING MONOCLONAL B-CELL LYMPHOCYTOSIS
Abigayle Sullivan, MD: BIRD FANCIER’S LUNG: AN UNDERDIAGNOSED CAUSE OF SHORTNESS OF BREATH
Nitin Gupta, DO: SUCCESSFUL EMERGENT CORONARY ARTERY BYPASS IN A WOMAN WITH POSTPARTUM SPONTANEOUS CORONARY ARTERY DISSECTION
Michelle Miles, DO: GI VARIANT OF LEMIERRE SYNDROME: COMPLETE OCCLUSION OF SUPERIOR MESENTERIC VEIN IN A 30-YEAR-OLD WITH APPENDICEAL ABSCESS
Adarsha Ojha, MD: BLEEDING LUNG AND BLOATING GUT: LANE HAMILTON SYNDROME
Abdul Siddiqui, MD: A CASE OF E-CIGARETTE OR VAPING PRODUCT USE-ASSOCIATED LUNG INJURY IN AN INFREQUENT VAPE USER
James Dugan, MD: EMPHYSEMA WITH PLACENTAL TRANSMOGRIFICATION AND LIPOMATOUS CHANGE
Daniel Condit, MD: DUPLICATE INFERIOR VENA CAVA AS A POTENTIAL PATHWAY FOR RECURRENT PULMONARY EMBOLISM
CHEST 2020 CHEST Challenge
1st Place
Case Western Reserve University (MetroHealth)
Enambir Josan, MD
Ishan Lalani, MD, MPH
Faisal Qadir, MD
Program Director: Ziad Shaman, MD, FCCP
2nd Place
SUNY Downstate
Suchit Khanijao, MD
Chetana Pendkar, MBBS
Ayla Zubair, MBBS
Program Director: Robert Foronjy, MD
3rd Place
NYP Brooklyn Methodist Hospital
John Gorski, MD
Sandi Khin, MD
Kinjal Patel, MD
Program Director: Anthony Saleh, MD, FCCP
ANNUAL AWARDS
Master FCCP
Nancy A. Collop MD, Master FCCP
College Medalist Award
Neil R. MacIntyre, MD, FCCP
Distinguished Service Award
Lisa K. Moores, MD, FCCP
Master Clinician Educator
William F. Kelly, MD, FCCP
David A. Schulman, MD, MPH, FCCP
Early Career Clinician Educator
Subani Chandra, MD, FCCP
Alfred Soffer Award for Editorial Excellence
Barbara Anderson, CHEST Staff
Laura Lipsey, CHEST Staff
Presidential Citation
Mangala Narasimhan, DO, FCCP
Renli Qiao, MD, PhD, FCCP
HONOR LECTURE AND MEMORIAL AWARDS
Edward C. Rosenow III, MD, Master FCCP/Master Teacher Endowed Honor Lecture Evolving Therapies in ANCA-Associated Vasculitides
Joseph P. Lynch, III, MD, FCCP
The lecture is generously funded by the CHEST Foundation.Distinguished Scientist Honor Lecture in Cardiopulmonary PhysiologyHelping the Dyspneic Patient: Clinical Physiology Matters!
Denis E. O’Donnell, MD, MBBCh, FCCP
The lecture is generously funded by the CHEST Foundation.Presidential Honor LectureCOPD Management: We’ve Come So Far
Darcy D. Marciniuk, MD, Master FCCP
Thomas L. Petty, MD, Master FCCP Memorial LectureReal World Research - What Would Dr. Petty Say?
Mary Hart, RRT, MS, FCCP
The lecture is generously funded by the CHEST Foundation.Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical VentilationNavigating to Home NIV Nirvana: What Would Margaret Do?
Peter C. Gay, MD, MS, FCCP
The Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical Ventilation is generously supported by International Ventilator Users Network of Post-Polio Health International and the CHEST Foundation.Pasquale Ciaglia Memorial Lecture in Interventional MedicineRaising the Bar: The Interventional Pulmonary Outcomes Group
Lonny B. Yarmus, DO, MBA, FCCP
The lecture is generously funded by the CHEST Foundation.
Roger C. Bone Memorial Lecture in Critical CareTo SIRS with Love: Dr. Roger Bone’s Continued Influence on Early Sepsis Care
Emanuel P. Rivers, MD, MPH, FCCP
The lecture is generously funded by the CHEST Foundation.Murray Kornfeld Memorial Founders LectureOur Pneumonia Journey: The Lungs and Beyond
Marcos I. Restrepo, MD, PhD, FCCP
The lecture is generously funded by the CHEST Foundation.
CHEST FOUNDATION GRANT AWARDS
The GlaxoSmithKline Distinguished Scholar in Respiratory Health
Deepa Gotur, MD, FCCP
Cytokine Release in SARS COV2 Viral Illness and Trends of Inflammasome Expression in Acute Respiratory Distress Syndrome Manifestations and ManagementThis grant is supported by an endowed fund from GlaxoSmithKline.CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency
Paul R. Ellis, MBChB
Cardiovascular Outcomes and Phenotypes in Pulmonary Exacerbations of Alpha-1 AntitrypsinThis grant is jointly supported by the CHEST Foundation and the Alpha-1 Foundation.CHEST Foundation Research Grant in Women’s Lung Health
Shannon E. Kay, MD
Sex-specific Gene Expression in AsthmaThis grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease
Davide Biondini, MD, PhD
Role of the Immune Check Points (CTLA-4 and PD-1) in the Development or Evasion of Smoking-Induced Chronic Obstructive Pulmonary Disease
Andrew J. Gangemi, MD
Are Sleep Health, Nicotine Metabolism, and Airway Inflammation Mechanisms for Differences in Lung Function between African American and Non-Hispanic White Smokers? A Proof-of-Concept ExaminationThese grants are supported by AstraZeneca LP.CHEST Foundation Research Grant in Critical Care
Mounica Vallurupalli, MD
Evaluating the Impact of Clonal Hematopoiesis on Host Immune Response During Sepsis
This grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Lung Cancer
Stefanie Mason, MD
Implications of Longitudinal Muscle-Mass Trajectories in Lung CancerThis grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Venous Thromboembolism
Jansen N. Seheult, MD, MBBCh
Untangling the NET: Neutrophil Activation as the Driver of Venous Thromboembolism in Coronavirus Disease 2019This grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases
Bryan A. Garcia, MD
Longitudinal Proteomic Endotyping of Patients with Nontuberculous Mycobacterial Lung InfectionsThis grant is supported by Insmed Incorporated.CHEST Foundation Research Grant in Cystic Fibrosis
Jeffrey Barry, MD
Eosinophilia as a Biomarker for Worse Outcomes in Cystic Fibrosis
Kristina Montemayor, MD
The Association of Sex Hormones and Respiratory Morbidity in Individuals with Cystic FibrosisThese grants are supported by Vertex Pharmaceuticals.John R. Addrizzo, MD, FCCP Research Grant in Sarcoidosis
Changwan Ryu, MD
Extracellular Matrix Proteins as a Biomarker for Stage IV SarcoidosisThis grant is in honor of John R. Addrizzo, MD, FCCP and is jointly supported by the Addrizzo family and the CHEST Foundation.CHEST Foundation Research Grant in Severe Asthma
Isaretta L. Riley, MD, MPH
Coping with Asthma through Life Management (CALM)This grant is funded by AstraZeneca LP.CHEST Foundation Research Grant in Pulmonary Fibrosis
Sarah Beshay, MD
COPA Syndrome-Associated Mutations in Lung Transplant Recipients for Pulmonary Fibrosis
Erica D. Farrand, MD
The Future of Telehealth in Interstitial Lung DiseaseThese grants are supported by Boehringer Ingelheim Pharmaceuticals and Genentech, Inc.CHEST Foundation Research Grant in Sleep Medicine
Tetyana Kendzerska, MD, PhD
The Role of Sleep and Circadian Disturbances in Cancer Development and Progression: A Historical Multicenter Clinical Cohort Study
Nancy Stewart, DO
Improving COPD/OSA Overlap Syndrome Pre-Discharge Care DeliveryThese grants are funded by Jazz Pharmaceuticals, Inc.CHEST Foundation and Association of Critical Care Medicine Program Directors Award Research Grant in Medical Education
Ilana R. Krumm, MD
What’s good about Soul Food? Discovering and Analyzing Elements of an ICU Team Group Discussion Which Improve Provider WellnessThis grant is jointly supported by the CHEST Foundation and APCCMPD.CHEST Foundation and American Thoracic Society Research Grant in Diversity
Thomas S. Valley, MD, MSc
Understanding Differences in Delivery of Care Processes for Respiratory Failure by Race/EthnicityThis grant is jointly supported by the CHEST Foundation and ATS.CHEST Foundation Research Grant in COVID-19
David Furfaro, MD
Subphenotypes, Inflammatory Profiles, and Antibody Response in COVID-19 ARDSThis grant is supported by the CHEST Foundation.CHEST Foundation and American Thoracic Society Grant in COVID-19 and Diversity
Peter D. Jackson, MD
The Effect of the COVID-19 Pandemic on Tuberculosis Care in UgandaThis grant is jointly supported by the CHEST Foundation and ATS.CHEST Foundation Research Grant in Ultrasonography and COVID-19
Marjan M. Islam, MD
Thoracic Ultrasound in COVID-19: A Prospective Study Using Lung and Diaphragm Ultrasound in Evaluating Dyspnea in ICU Survivors with COVID-19 in a Post-ICU Clinic
Siddharth Dugar, MBBS
Spontaneous Echo Contrast in Lower Extremity and Correlation with Venous Velocity and Subsequent Deep Venous Thrombosis in Critically Ill COVID-19 PatientsThis grant is jointly supported by the CHEST Foundation and FUJIFILM SonoSite.
CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP
Ivan Nemorin, MBA, MS, RRT
Healthier Homes for Children-Community Asthma Prevention Program
Joseph Huang, MD
East Africa Training Initiative (EATI)
Aninda Das, MD, MBBS
Screening for Childhood Tuberculosis in Children 0-4 years of Age with Moderate to Severe Malnutrition in a Rural District of West Bengal, India
Trishual Siddharthan, MD
Establishing a Pulmonary and Critical Care Training Program in Uganda
Marina Lima, MD, MSc
Asmaland: The First Gamified Pediatric Asthma Educational Program in Portuguese
Roberta M. Kato, MD
Lung Power
These grants are supported by the CHEST Foundation.Alfred Soffer Research Award Winners
Mazen O. Al-Qadi, MD: RESPIRATORY VARIATION IN RIGHT ATRIAL PRESSURE PREDICTS RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH PRE-CAPILLARY PULMONARY HYPERTENSION
Valerie G. Press, MD: COST SAVING SIMULATION FOR THE TRANSITION FROM NEBULIZER TO COMBINATION OF NEBULIZER AND METERED-DOSE INHALERS (MD)
Young Investigator Award Winners
Gabriel E. Ortiz Jaimes, MD: CORRELATION OF CARDIAC OUTPUT MEASUREMENT BY GOAL-DIRECTED ECHOCARDIOGRAPHY PERFORMED BY INTENSIVISTS VS PULMONARY ARTERY CATHETER
Palakkumar Patel, MD: IMPACT OF HAVING PULMONARY HYPERTENSION IN PATIENTS ADMITTED WITH ACUTE EXACERBATION OF COPD IN THEIR HEALTHCARE UTILIZATION AND READMISSION: A US POPULATION COHORT STUDY
Top 5 Abstract Posters
Winner: Amr Alwakeel, MD: IMPACT OF A PLEURAL CARE PROGRAM ON THE PATHWAY TO DEFINITIVE PALLIATION OF MALIGNANT PLEURAL EFFUSIONS: A PRE-AND POST STUDY
Winner: Konstantinos Zorbas, MD: A SIMPLE PREDICTION SCORE FOR POSTOPERATIVE DEATH AFTER DECORTICATION
Winner: Yichen Wang, MD, MSc: CORONAVIRUS-RELATED HOSPITAL ADMISSIONS IN THE UNITED STATES IN 2016-2017
Runner up: Daniel Ospina-Delgado, MD: CHARACTERIZATION OF LARYNGEAL DISORDERS IN PATIENTS WITH EXCESSIVE CENTRAL AIRWAY COLLAPSE
Runner up: Vishal Vashistha, MD: TREATMENT PATTERNS AMONG LOWER-INCOME INDIAN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS OR ALK REARRANGEMENTS
Case Report Poster Winners
Faiza Khalid, MD: FORME FUSTE OF INTERMEDIATE SYNDROME (IMS) IN ORGANOPHOSPHATE POISOING (OPP): EXPERT OPINION GUIDELINE WITHOUT CLEAR END-POINT.
William Meng, MD: VINGT MILLE LIEUES SOUS LES MERS: A POISONOUS GUEST FROM THE BLUE SEA TOXIC INHALATION OF CORAL PALYTOXIN
Dhruv Amratia, MD: PULMONARY BLASTOMA: A RARE FORM OF LUNG CANCER
Melinda Becker, MD: ECMO-ASSISTED BRONCHOSCOPY FOR NEAR-COMPLETE TRACHEAL OBSTRUCTION
Brittany Blass, PA-C: A CASE OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS WITH UNDERLYING MONOCLONAL B-CELL LYMPHOCYTOSIS
Abigayle Sullivan, MD: BIRD FANCIER’S LUNG: AN UNDERDIAGNOSED CAUSE OF SHORTNESS OF BREATH
Nitin Gupta, DO: SUCCESSFUL EMERGENT CORONARY ARTERY BYPASS IN A WOMAN WITH POSTPARTUM SPONTANEOUS CORONARY ARTERY DISSECTION
Michelle Miles, DO: GI VARIANT OF LEMIERRE SYNDROME: COMPLETE OCCLUSION OF SUPERIOR MESENTERIC VEIN IN A 30-YEAR-OLD WITH APPENDICEAL ABSCESS
Adarsha Ojha, MD: BLEEDING LUNG AND BLOATING GUT: LANE HAMILTON SYNDROME
Abdul Siddiqui, MD: A CASE OF E-CIGARETTE OR VAPING PRODUCT USE-ASSOCIATED LUNG INJURY IN AN INFREQUENT VAPE USER
James Dugan, MD: EMPHYSEMA WITH PLACENTAL TRANSMOGRIFICATION AND LIPOMATOUS CHANGE
Daniel Condit, MD: DUPLICATE INFERIOR VENA CAVA AS A POTENTIAL PATHWAY FOR RECURRENT PULMONARY EMBOLISM
CHEST 2020 CHEST Challenge
1st Place
Case Western Reserve University (MetroHealth)
Enambir Josan, MD
Ishan Lalani, MD, MPH
Faisal Qadir, MD
Program Director: Ziad Shaman, MD, FCCP
2nd Place
SUNY Downstate
Suchit Khanijao, MD
Chetana Pendkar, MBBS
Ayla Zubair, MBBS
Program Director: Robert Foronjy, MD
3rd Place
NYP Brooklyn Methodist Hospital
John Gorski, MD
Sandi Khin, MD
Kinjal Patel, MD
Program Director: Anthony Saleh, MD, FCCP
ANNUAL AWARDS
Master FCCP
Nancy A. Collop MD, Master FCCP
College Medalist Award
Neil R. MacIntyre, MD, FCCP
Distinguished Service Award
Lisa K. Moores, MD, FCCP
Master Clinician Educator
William F. Kelly, MD, FCCP
David A. Schulman, MD, MPH, FCCP
Early Career Clinician Educator
Subani Chandra, MD, FCCP
Alfred Soffer Award for Editorial Excellence
Barbara Anderson, CHEST Staff
Laura Lipsey, CHEST Staff
Presidential Citation
Mangala Narasimhan, DO, FCCP
Renli Qiao, MD, PhD, FCCP
HONOR LECTURE AND MEMORIAL AWARDS
Edward C. Rosenow III, MD, Master FCCP/Master Teacher Endowed Honor Lecture Evolving Therapies in ANCA-Associated Vasculitides
Joseph P. Lynch, III, MD, FCCP
The lecture is generously funded by the CHEST Foundation.Distinguished Scientist Honor Lecture in Cardiopulmonary PhysiologyHelping the Dyspneic Patient: Clinical Physiology Matters!
Denis E. O’Donnell, MD, MBBCh, FCCP
The lecture is generously funded by the CHEST Foundation.Presidential Honor LectureCOPD Management: We’ve Come So Far
Darcy D. Marciniuk, MD, Master FCCP
Thomas L. Petty, MD, Master FCCP Memorial LectureReal World Research - What Would Dr. Petty Say?
Mary Hart, RRT, MS, FCCP
The lecture is generously funded by the CHEST Foundation.Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical VentilationNavigating to Home NIV Nirvana: What Would Margaret Do?
Peter C. Gay, MD, MS, FCCP
The Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical Ventilation is generously supported by International Ventilator Users Network of Post-Polio Health International and the CHEST Foundation.Pasquale Ciaglia Memorial Lecture in Interventional MedicineRaising the Bar: The Interventional Pulmonary Outcomes Group
Lonny B. Yarmus, DO, MBA, FCCP
The lecture is generously funded by the CHEST Foundation.
Roger C. Bone Memorial Lecture in Critical CareTo SIRS with Love: Dr. Roger Bone’s Continued Influence on Early Sepsis Care
Emanuel P. Rivers, MD, MPH, FCCP
The lecture is generously funded by the CHEST Foundation.Murray Kornfeld Memorial Founders LectureOur Pneumonia Journey: The Lungs and Beyond
Marcos I. Restrepo, MD, PhD, FCCP
The lecture is generously funded by the CHEST Foundation.
CHEST FOUNDATION GRANT AWARDS
The GlaxoSmithKline Distinguished Scholar in Respiratory Health
Deepa Gotur, MD, FCCP
Cytokine Release in SARS COV2 Viral Illness and Trends of Inflammasome Expression in Acute Respiratory Distress Syndrome Manifestations and ManagementThis grant is supported by an endowed fund from GlaxoSmithKline.CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency
Paul R. Ellis, MBChB
Cardiovascular Outcomes and Phenotypes in Pulmonary Exacerbations of Alpha-1 AntitrypsinThis grant is jointly supported by the CHEST Foundation and the Alpha-1 Foundation.CHEST Foundation Research Grant in Women’s Lung Health
Shannon E. Kay, MD
Sex-specific Gene Expression in AsthmaThis grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease
Davide Biondini, MD, PhD
Role of the Immune Check Points (CTLA-4 and PD-1) in the Development or Evasion of Smoking-Induced Chronic Obstructive Pulmonary Disease
Andrew J. Gangemi, MD
Are Sleep Health, Nicotine Metabolism, and Airway Inflammation Mechanisms for Differences in Lung Function between African American and Non-Hispanic White Smokers? A Proof-of-Concept ExaminationThese grants are supported by AstraZeneca LP.CHEST Foundation Research Grant in Critical Care
Mounica Vallurupalli, MD
Evaluating the Impact of Clonal Hematopoiesis on Host Immune Response During Sepsis
This grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Lung Cancer
Stefanie Mason, MD
Implications of Longitudinal Muscle-Mass Trajectories in Lung CancerThis grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Venous Thromboembolism
Jansen N. Seheult, MD, MBBCh
Untangling the NET: Neutrophil Activation as the Driver of Venous Thromboembolism in Coronavirus Disease 2019This grant is supported by the CHEST Foundation.CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases
Bryan A. Garcia, MD
Longitudinal Proteomic Endotyping of Patients with Nontuberculous Mycobacterial Lung InfectionsThis grant is supported by Insmed Incorporated.CHEST Foundation Research Grant in Cystic Fibrosis
Jeffrey Barry, MD
Eosinophilia as a Biomarker for Worse Outcomes in Cystic Fibrosis
Kristina Montemayor, MD
The Association of Sex Hormones and Respiratory Morbidity in Individuals with Cystic FibrosisThese grants are supported by Vertex Pharmaceuticals.John R. Addrizzo, MD, FCCP Research Grant in Sarcoidosis
Changwan Ryu, MD
Extracellular Matrix Proteins as a Biomarker for Stage IV SarcoidosisThis grant is in honor of John R. Addrizzo, MD, FCCP and is jointly supported by the Addrizzo family and the CHEST Foundation.CHEST Foundation Research Grant in Severe Asthma
Isaretta L. Riley, MD, MPH
Coping with Asthma through Life Management (CALM)This grant is funded by AstraZeneca LP.CHEST Foundation Research Grant in Pulmonary Fibrosis
Sarah Beshay, MD
COPA Syndrome-Associated Mutations in Lung Transplant Recipients for Pulmonary Fibrosis
Erica D. Farrand, MD
The Future of Telehealth in Interstitial Lung DiseaseThese grants are supported by Boehringer Ingelheim Pharmaceuticals and Genentech, Inc.CHEST Foundation Research Grant in Sleep Medicine
Tetyana Kendzerska, MD, PhD
The Role of Sleep and Circadian Disturbances in Cancer Development and Progression: A Historical Multicenter Clinical Cohort Study
Nancy Stewart, DO
Improving COPD/OSA Overlap Syndrome Pre-Discharge Care DeliveryThese grants are funded by Jazz Pharmaceuticals, Inc.CHEST Foundation and Association of Critical Care Medicine Program Directors Award Research Grant in Medical Education
Ilana R. Krumm, MD
What’s good about Soul Food? Discovering and Analyzing Elements of an ICU Team Group Discussion Which Improve Provider WellnessThis grant is jointly supported by the CHEST Foundation and APCCMPD.CHEST Foundation and American Thoracic Society Research Grant in Diversity
Thomas S. Valley, MD, MSc
Understanding Differences in Delivery of Care Processes for Respiratory Failure by Race/EthnicityThis grant is jointly supported by the CHEST Foundation and ATS.CHEST Foundation Research Grant in COVID-19
David Furfaro, MD
Subphenotypes, Inflammatory Profiles, and Antibody Response in COVID-19 ARDSThis grant is supported by the CHEST Foundation.CHEST Foundation and American Thoracic Society Grant in COVID-19 and Diversity
Peter D. Jackson, MD
The Effect of the COVID-19 Pandemic on Tuberculosis Care in UgandaThis grant is jointly supported by the CHEST Foundation and ATS.CHEST Foundation Research Grant in Ultrasonography and COVID-19
Marjan M. Islam, MD
Thoracic Ultrasound in COVID-19: A Prospective Study Using Lung and Diaphragm Ultrasound in Evaluating Dyspnea in ICU Survivors with COVID-19 in a Post-ICU Clinic
Siddharth Dugar, MBBS
Spontaneous Echo Contrast in Lower Extremity and Correlation with Venous Velocity and Subsequent Deep Venous Thrombosis in Critically Ill COVID-19 PatientsThis grant is jointly supported by the CHEST Foundation and FUJIFILM SonoSite.
CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP
Ivan Nemorin, MBA, MS, RRT
Healthier Homes for Children-Community Asthma Prevention Program
Joseph Huang, MD
East Africa Training Initiative (EATI)
Aninda Das, MD, MBBS
Screening for Childhood Tuberculosis in Children 0-4 years of Age with Moderate to Severe Malnutrition in a Rural District of West Bengal, India
Trishual Siddharthan, MD
Establishing a Pulmonary and Critical Care Training Program in Uganda
Marina Lima, MD, MSc
Asmaland: The First Gamified Pediatric Asthma Educational Program in Portuguese
Roberta M. Kato, MD
Lung Power
These grants are supported by the CHEST Foundation.Alfred Soffer Research Award Winners
Mazen O. Al-Qadi, MD: RESPIRATORY VARIATION IN RIGHT ATRIAL PRESSURE PREDICTS RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH PRE-CAPILLARY PULMONARY HYPERTENSION
Valerie G. Press, MD: COST SAVING SIMULATION FOR THE TRANSITION FROM NEBULIZER TO COMBINATION OF NEBULIZER AND METERED-DOSE INHALERS (MD)
Young Investigator Award Winners
Gabriel E. Ortiz Jaimes, MD: CORRELATION OF CARDIAC OUTPUT MEASUREMENT BY GOAL-DIRECTED ECHOCARDIOGRAPHY PERFORMED BY INTENSIVISTS VS PULMONARY ARTERY CATHETER
Palakkumar Patel, MD: IMPACT OF HAVING PULMONARY HYPERTENSION IN PATIENTS ADMITTED WITH ACUTE EXACERBATION OF COPD IN THEIR HEALTHCARE UTILIZATION AND READMISSION: A US POPULATION COHORT STUDY
Top 5 Abstract Posters
Winner: Amr Alwakeel, MD: IMPACT OF A PLEURAL CARE PROGRAM ON THE PATHWAY TO DEFINITIVE PALLIATION OF MALIGNANT PLEURAL EFFUSIONS: A PRE-AND POST STUDY
Winner: Konstantinos Zorbas, MD: A SIMPLE PREDICTION SCORE FOR POSTOPERATIVE DEATH AFTER DECORTICATION
Winner: Yichen Wang, MD, MSc: CORONAVIRUS-RELATED HOSPITAL ADMISSIONS IN THE UNITED STATES IN 2016-2017
Runner up: Daniel Ospina-Delgado, MD: CHARACTERIZATION OF LARYNGEAL DISORDERS IN PATIENTS WITH EXCESSIVE CENTRAL AIRWAY COLLAPSE
Runner up: Vishal Vashistha, MD: TREATMENT PATTERNS AMONG LOWER-INCOME INDIAN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS OR ALK REARRANGEMENTS
Case Report Poster Winners
Faiza Khalid, MD: FORME FUSTE OF INTERMEDIATE SYNDROME (IMS) IN ORGANOPHOSPHATE POISOING (OPP): EXPERT OPINION GUIDELINE WITHOUT CLEAR END-POINT.
William Meng, MD: VINGT MILLE LIEUES SOUS LES MERS: A POISONOUS GUEST FROM THE BLUE SEA TOXIC INHALATION OF CORAL PALYTOXIN
Dhruv Amratia, MD: PULMONARY BLASTOMA: A RARE FORM OF LUNG CANCER
Melinda Becker, MD: ECMO-ASSISTED BRONCHOSCOPY FOR NEAR-COMPLETE TRACHEAL OBSTRUCTION
Brittany Blass, PA-C: A CASE OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS WITH UNDERLYING MONOCLONAL B-CELL LYMPHOCYTOSIS
Abigayle Sullivan, MD: BIRD FANCIER’S LUNG: AN UNDERDIAGNOSED CAUSE OF SHORTNESS OF BREATH
Nitin Gupta, DO: SUCCESSFUL EMERGENT CORONARY ARTERY BYPASS IN A WOMAN WITH POSTPARTUM SPONTANEOUS CORONARY ARTERY DISSECTION
Michelle Miles, DO: GI VARIANT OF LEMIERRE SYNDROME: COMPLETE OCCLUSION OF SUPERIOR MESENTERIC VEIN IN A 30-YEAR-OLD WITH APPENDICEAL ABSCESS
Adarsha Ojha, MD: BLEEDING LUNG AND BLOATING GUT: LANE HAMILTON SYNDROME
Abdul Siddiqui, MD: A CASE OF E-CIGARETTE OR VAPING PRODUCT USE-ASSOCIATED LUNG INJURY IN AN INFREQUENT VAPE USER
James Dugan, MD: EMPHYSEMA WITH PLACENTAL TRANSMOGRIFICATION AND LIPOMATOUS CHANGE
Daniel Condit, MD: DUPLICATE INFERIOR VENA CAVA AS A POTENTIAL PATHWAY FOR RECURRENT PULMONARY EMBOLISM
CHEST 2020 CHEST Challenge
1st Place
Case Western Reserve University (MetroHealth)
Enambir Josan, MD
Ishan Lalani, MD, MPH
Faisal Qadir, MD
Program Director: Ziad Shaman, MD, FCCP
2nd Place
SUNY Downstate
Suchit Khanijao, MD
Chetana Pendkar, MBBS
Ayla Zubair, MBBS
Program Director: Robert Foronjy, MD
3rd Place
NYP Brooklyn Methodist Hospital
John Gorski, MD
Sandi Khin, MD
Kinjal Patel, MD
Program Director: Anthony Saleh, MD, FCCP
CHEST Foundation vision for 2021 and beyond
In the year of COVID-19, we saw unprecedented changes in our environment and social interactions. Almost nothing was as it should be—sports championships in a “bubble,” social distancing, limited travel, economic hardships, and, of course, the devastating effects on the health of people all over the world. CHEST did not shy away from the challenges of COVID-19. Instead, we accelerated our focus on education, patient care, research, and advocacy to assist clinicians caring for affected patients. The CHEST Foundation, the philanthropic arm of CHEST, contributed to this effort by funding research and community service grants and distributing over 14,000 pieces of PPE to health workers and the public.
Amid social protests, CHEST issued statements supporting inclusion and diversity and called for improving health care disparities. To better understand how these important issues interact, the CHEST Foundation began conducting listening tours across the country
to learn what is important to patients and what barriers they face. These lessons will influence how the foundation implements its current programs and designs future programs. Over the next few months, the CHEST Foundation will set in motion a course of action to support valuable programs in these areas. We will focus on three main themes.
First, we will utilize the strength of CHEST by inviting fellows to participate in CHEST Foundation activities and serve on our committees. By creating an atmosphere of inclusion and collegiality, we believe that fellows will better understand the CHEST Foundation’s goals and commit themselves to strengthening the foundation for years to come.
Second, we want to establish relationships with organizations outside of CHEST. Although our partnerships with health care industry organizations are strong, we have few robust alliances in the non-endemic space. Corporations espouse wellness, and we have experts all over the world who can address the needs and concerns of these companies. Preliminary exploration tells us that non-endemic corporations have an interest in what we can offer.
Third, we want to grow the corpus of the CHEST Foundation. Dreams without funding become only aspirations, but dreams with funding become reality. Without a solid corpus, we operate on a short-term plan. CHEST has some of the most influential leaders in the fields of pulmonary, critical care, and sleep medicine. Together, we can develop programs that can significantly impact the lives of the people we serve.
The CHEST Foundation looks forward to building on past successes and tackling new challenges. On behalf of CHEST’s Board of Trustees and the gifted staff, I invite you to join us to reach these goals.
In the year of COVID-19, we saw unprecedented changes in our environment and social interactions. Almost nothing was as it should be—sports championships in a “bubble,” social distancing, limited travel, economic hardships, and, of course, the devastating effects on the health of people all over the world. CHEST did not shy away from the challenges of COVID-19. Instead, we accelerated our focus on education, patient care, research, and advocacy to assist clinicians caring for affected patients. The CHEST Foundation, the philanthropic arm of CHEST, contributed to this effort by funding research and community service grants and distributing over 14,000 pieces of PPE to health workers and the public.
Amid social protests, CHEST issued statements supporting inclusion and diversity and called for improving health care disparities. To better understand how these important issues interact, the CHEST Foundation began conducting listening tours across the country
to learn what is important to patients and what barriers they face. These lessons will influence how the foundation implements its current programs and designs future programs. Over the next few months, the CHEST Foundation will set in motion a course of action to support valuable programs in these areas. We will focus on three main themes.
First, we will utilize the strength of CHEST by inviting fellows to participate in CHEST Foundation activities and serve on our committees. By creating an atmosphere of inclusion and collegiality, we believe that fellows will better understand the CHEST Foundation’s goals and commit themselves to strengthening the foundation for years to come.
Second, we want to establish relationships with organizations outside of CHEST. Although our partnerships with health care industry organizations are strong, we have few robust alliances in the non-endemic space. Corporations espouse wellness, and we have experts all over the world who can address the needs and concerns of these companies. Preliminary exploration tells us that non-endemic corporations have an interest in what we can offer.
Third, we want to grow the corpus of the CHEST Foundation. Dreams without funding become only aspirations, but dreams with funding become reality. Without a solid corpus, we operate on a short-term plan. CHEST has some of the most influential leaders in the fields of pulmonary, critical care, and sleep medicine. Together, we can develop programs that can significantly impact the lives of the people we serve.
The CHEST Foundation looks forward to building on past successes and tackling new challenges. On behalf of CHEST’s Board of Trustees and the gifted staff, I invite you to join us to reach these goals.
In the year of COVID-19, we saw unprecedented changes in our environment and social interactions. Almost nothing was as it should be—sports championships in a “bubble,” social distancing, limited travel, economic hardships, and, of course, the devastating effects on the health of people all over the world. CHEST did not shy away from the challenges of COVID-19. Instead, we accelerated our focus on education, patient care, research, and advocacy to assist clinicians caring for affected patients. The CHEST Foundation, the philanthropic arm of CHEST, contributed to this effort by funding research and community service grants and distributing over 14,000 pieces of PPE to health workers and the public.
Amid social protests, CHEST issued statements supporting inclusion and diversity and called for improving health care disparities. To better understand how these important issues interact, the CHEST Foundation began conducting listening tours across the country
to learn what is important to patients and what barriers they face. These lessons will influence how the foundation implements its current programs and designs future programs. Over the next few months, the CHEST Foundation will set in motion a course of action to support valuable programs in these areas. We will focus on three main themes.
First, we will utilize the strength of CHEST by inviting fellows to participate in CHEST Foundation activities and serve on our committees. By creating an atmosphere of inclusion and collegiality, we believe that fellows will better understand the CHEST Foundation’s goals and commit themselves to strengthening the foundation for years to come.
Second, we want to establish relationships with organizations outside of CHEST. Although our partnerships with health care industry organizations are strong, we have few robust alliances in the non-endemic space. Corporations espouse wellness, and we have experts all over the world who can address the needs and concerns of these companies. Preliminary exploration tells us that non-endemic corporations have an interest in what we can offer.
Third, we want to grow the corpus of the CHEST Foundation. Dreams without funding become only aspirations, but dreams with funding become reality. Without a solid corpus, we operate on a short-term plan. CHEST has some of the most influential leaders in the fields of pulmonary, critical care, and sleep medicine. Together, we can develop programs that can significantly impact the lives of the people we serve.
The CHEST Foundation looks forward to building on past successes and tackling new challenges. On behalf of CHEST’s Board of Trustees and the gifted staff, I invite you to join us to reach these goals.